

**QUEEN'S UNIVERSITY  
DEPARTMENT OF PATHOLOGY**



**FACULTY OF HEALTH SCIENCES  
ANNUAL REPORT  
2002**

**DR. PAUL MANLEY, MD – CHAIRMAN (January 1-June 30, 2002)**  
**DR. IAIN YOUNG, MD – CHAIRMAN (July 1-December 31, 2002)**

**DEPARTMENT OF PATHOLOGY  
2002  
ANNUAL REPORT**

**TABLE OF CONTENTS**

Introduction

Faculty, Administration and Laboratory Managers and Supervisors

Laboratory Medicine and Pathology

Clinical Laboratories of Eastern Ontario (CLEO)

Personnel, Awards and Significant Events

Undergraduate, Graduate and Postgraduate Educational Programs

Research Projects and Grants in Progress

Department of Pathology Visiting Lecturers

Senior Staff Department of Pathology and Queen's University Lectures

Senior Staff Department of Pathology - Invited Lectures Outside of Queen's & KGH

Senior Staff Committees

Editorial Boards and Grant Review Committees

Full Papers Published and in Press

Abstracts

(Report written April 2003)

**FACULTY, ADMINISTRATION  
AND  
LABORATORY MANAGERS AND SUPERVISORS**

**DEPARTMENT OF PATHOLOGY  
FACULTY**

**2002**

**PROFESSOR AND HEAD**

Dr. Paul Manley – January 1-June30, 2002  
Dr. Iain Young – July 1-December 31, 2002

**PROFESSORS**

Dr. A.F. Clark\*  
Dr. S. Cole  
Dr. R. Deeley  
Dr. B. Elliott  
Dr. R. Kisilevsky (On sabbatical Sep. 1, 2001-Aug. 30, 2002)  
Dr. D. Lillicrap  
Dr. S. Ludwin  
Dr. P.G. Young\*

**ASSOCIATE PROFESSORS**

Dr. S. Boag  
Dr. C. Collier  
Dr. D. Dexter  
Dr. W.A. Fletcher (retired June 30, 2002)  
Dr. S. Ford (retired June 30, 2002)  
Dr. P. Greer  
Dr. M. Khalifa (primary faculty March 1, 2002)  
Dr. D. LeBrun  
Dr. D. Maurice\*  
Dr. C. Mueller\*  
Dr. L. Mulligan\*  
Dr. M. Petkovich\*  
Dr. L. Raptis\*  
Dr. J. Rossiter  
Dr. S. SenGupta  
Dr. L. Shepherd  
Dr. S. Taylor  
Dr. L. Tomalty\*  
Dr. D. Zoutman

**ASSISTANT PROFESSORS**

Dr. T. Childs (effective July 1, 2002)  
Dr. G. Evans\*  
Dr. C. Forster-Gibson\*  
Dr. K. Harrison  
Dr. D. Hurlbut  
Dr. P. Isotalo (effective August 18, 2002)  
Dr. T. Karnauchow  
Dr. D. Lee\*

## **ASSISTANT PROFESSORS**

(cont'd)

Dr. J. MacKenzie\*  
Dr. D. Rapson  
Dr. M. Raymond  
Dr. C. Rowlands

## **LECTURER**

Dr. J. Raymond (retired December 31, 2002)

## **ADJUNCT ACADEMIC GROUP I**

Dr. J. Ancsin  
Dr. D. Connor  
Dr. S. Davey  
Dr. H. Feilotter  
Dr. D. Haust  
Mr. L. Kennedy  
Dr. A. Lagarde  
Mr. D. Piper  
Dr. D.M. Robertson, Emeritus  
Dr. J. Samis  
Dr. V. Walley

## **ADMINISTRATION**

Laboratory Manager	- Mr. David Piper (retired Nov. 30/02)
Administrative Assistant	- Mrs. Marg McIlroy
Administrative Assistant	- Mrs. Barb Latimer

## **LABORATORY MANAGERS AND SUPERVISORS**

Anatomic Pathology	- Mr. Dave More
Chemistry	- Mrs. Mary Waugh
Cytogenetics	- Ms. Anne Hanley
Microbiology	- Ms. Linda Fidler
CLEO	- Mr. Dave More

**\*Cross-Appointed Staff**

**LABORATORY MEDICINE  
AND  
PATHOLOGY**

## INTRODUCTION & EXECUTIVE SUMMARY

Pathology as a discipline bridges the interface between basic medical science and clinical practice.

Therefore the role of the Queen's Department of Pathology is distinctive at the Medical School; while playing a major role in the educational and research aspects of the school, it functions as both a basic science and a clinical department; and is also responsible for one of the most technically and administratively complex service departments in the affiliated hospitals.

The Department has achieved excellence in many areas of its mandate, by building on a policy of commitment to academic excellence, taking into consideration the unique features offered by the local Queen's and regional environments. Of great importance has been the establishment of a common set of values throughout the Department, in which mutual respect for excellence in all of the various aspects of Departmental work has been achieved among its members, and in which there has been little internal dissension about the need to mutually support the various diverse endeavours of the Department. In these endeavours, the strategic plan of the Department, and its vision are remarkably consonant with the recently articulated Faculty Vision Statement.

The educational aspects of the Department have traditionally been very strong. The Pathology Department is unique in that it offers a complete range of educational facilities, from Undergraduate Medical, Undergraduate Life Sciences and Graduate Studies, to Postgraduate Resident levels. The evolution of teaching to Undergraduate Medical students has progressed from the delivery of traditional courses in General and Special Pathology under the old curriculum, to the integrated teaching of the new curriculum, a process still in progress, but one which has been readily embraced by the Department, which has shown a willingness to take a leadership role in the process. The Undergraduate Life Science programme has progressively expanded at Queen's, and concurrent with this, the enrolment in courses given by the Pathology Department has steadily increased. The Pathology Department is actively pursuing, together with other Basic Science departments, methods of collaborative teaching in this important programme. The Department's Graduate Studies programme has increased dramatically since its inception, with a major increase in a number of Graduate students, including progressively more PhD students, studying and doing research within the Department.

Traditionally, residency training in the Department has been very strong, with 4 programmes recently re-accredited by the Royal College of Physicians of Canada, being offered. Queen's graduates have had a remarkably high rate of success in examinations in these programmes, and have gone on to take jobs in both the Academic and the Non-University sectors. The General Pathology training programme for years has been considered one of the best of its kind in the country, and the Neuropathology training programme has attracted applicants from around the world, who have then gone on to important academic positions in the country. The Pathology training programme like those all around the country faces tremendous challenges due to the restrictions on positions and entry imposed by the Provincial governments. Residency numbers are at their lowest levels in 30 years in Canada and we are facing a significant shortage of academic pathologists imminently.

Since the 1950's, the Department, starting under the Headship of Dr. Robert More, has developed into an extremely strong academic unit. Although the Department is of relatively small size, in concert with the size of Queen's Medical School and the affiliated hospitals, it has achieved a level of academic excellence, far in excess of that expected for its numbers. The Department attracts external funding of approximately \$3.6 million annually, in competitive grants, a figure

among the highest in the Medical School in absolute terms. (It should be pointed out that this figure covers only those Faculty members having a Primary appointment in Pathology - those with joint appointments in Pathology whose home department is elsewhere are not included in these statistics). In comparison to other medical schools or on a FTE basis, this puts our Department at the pinnacle of departments across Canada. Pathology Department researchers have 4 times within the last 10 years won the University-wide Excellence in Research Award, a record unmatched by any other university department. Research groupings in the Department, in Cancer, Haemostasis, Amyloidosis, Neuroscience and Human Genetics have been well established, with multiple links to researchers in other departments across the university, and internationally. In this we have been the leaders in the development of highly productive research groups.

The service aspects of the Department take place mainly in the affiliated hospitals, Kingston General and Hotel Dieu. There is a complex administrative structure, which has traditionally encompassed 2 separate hospitals. In advance of the restructuring in the city of Kingston, a single Department sited primarily at Kingston General Hospital was developed in 1996. The clinical activities cover a wide range of specialist's and sub-specialist's expertise.

A major enterprise of a great practical and academic importance is the Clinical Laboratories of Eastern Ontario Regional Programme. This has been a concerted initiative over the last 15 years, involving the provision of laboratory services, expertise and increasingly education by the Queen's academic department to the hospitals in the region of South Eastern Ontario. This exercise is a novel one in Ontario with the potential to serve as a model not only for other Academic Pathology Departments across the Province, but for Clinical Departments as well.

The Department is thus fulfilling the mandate of the Dean's Vision Statement of the Medical School, in the Generation, Transmission and Application of knowledge. It has long concentrated on the training of excellent General Pathologists, while at the same time achieving international stature in the provision of selected sub-specialists' services. In the service and education sectors, the Department has served not only the entire local area, but has now embarked on an ambitious regional programme, taking into consideration the unique features of the South Eastern Ontario Health Sciences environment. In the field of research, or knowledge generation, international excellence has been achieved, through the formation of collaborative groups both within and outside the Department.



**PERSONNEL AWARDS  
AND  
SIGNIFICANT EVENTS**

## **PERSONNEL AWARDS AND SIGNIFICANT EVENTS**

### **AWARDS**

**ONTARIO DISTINGUISHED RESEARCH AWARD, 2002 – Dr. Susan Cole**

#### **ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA**

**Dr. Robert Kisilevsky** received the Detweiler Travelling Fellow Award which he held at the Department of Medical Biochemistry and Microbiology, University of Uppsala, Sweden from 2001 September to 2002 August.

#### **CIHR - CANADA RESEARCH CHAIRS**

**Dr. Susan Cole (Cancer Biology)** and **Dr. David Lillicrap (Molecular Hemostasis)** were awarded Tier I Canada Research Chairs, 2001-2008.

#### **ONTARIO HEART & STROKE FOUNDATION OF ONTARIO**

**Dr. David Lillicrap** has been an Ontario Heart and Stroke Foundation Career Investigator since 1995.

#### **THE ALAN BLIZZARD AWARD**

**Dr. Sherry Taylor** received an Honourable Mention through the Society for Teaching and Learning in Higher Education.

#### **ROBERT PRENTICE AWARD - RESIDENT PATHOLOGY TEACHING**

Not presented this year.

#### **2001 R.S.A. PRENTICE AWARD**

Not presented this year.

## SIGNIFICANT EVENTS

**Dr. Peter Greer** received Tenure, effective July 1, 2002.

**Dr. Lois Mulligan** was promoted to Full Professor, effective July 1, 2002.

**Mr. Lou Franchi**, Chief Technologist in Histology since 1967, retired May 10, 2002.

**Mr. Dave Piper**, Administrative Officer, retired November 30, 2002.

**Dr. Jenny Raymond**, retired December 31, 2002.

**Drs. A. Fletcher and S. Ford** retired effective July 1, 2002.

**Mr. Dave Piper**, Administrative Director, retired effective November 30, 2002.

### **2<sup>nd</sup> Annual Nathan Kaufman Lecturer**

**Dr. Janet Rossant**, Joint Head, Program in Development and Fetal Health at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto; and Professor in the Department of Molecular and Medical Genetics and the Department of Obstetrics/Gynecology, University of Toronto

Thursday, January 10, 2002

*“Signalling Pathways in Early Mouse Development”*

### **Enrichment Mini-Course 2002**

Pathology minicourse by Ron Saulnier, May 2002

### **Contact information**

Home Unit 9-221 Station Blvd Ottawa ON, K1G 6L8 613-248-1260 <a href="mailto:ron.saulnier@rogers.com">ron.saulnier@rogers.com</a>	work: Ottawa Health Research Institute 501 Smyth Rd, Ottawa ON K1H 8L6 613-739-6634 <a href="mailto:rsaulnier@ohri.ca">rsaulnier@ohri.ca</a>
--	--

The pathology course I give is a combination of lectures from me and guests as well as class activities and handouts and visits to various facilities around campus. The main objectives of the course are to:

1. introduce them to the study of diseases
2. Give them exposure to several health related professions
3. learn new subjects in biology at a level higher than high school

Although the sequence in which the events occur varies from year to year as I give priority to the activities and guest. I schedule my lectures in whatever time is left. I try to be flexible in the time frame so that if an activity is scheduled for an hour but there is lots of interest and questions I let it go until is done. The course is also purposely organized to get more interesting as the week progresses in that the lecture are concentrated in the first day in a half and then the activities start. The Friday morning is mostly finishing loose ends and going over topics of interest.

They start the week with some introductory material on pathology and the etiology of diseases. They receive a number of handouts and a couple of exercises. The activities on handouts are the medical terminology, find a word, matching, filling out list for cancer related questions and matching the cancer with the organ or tissue from which it originates. Also given are a couple of exercises to get them to talk to each other and problem solve as a team. They are given statements about a medical condition, which is either true or false. They are supposed to ask their

classmates whether they think it is true or false until they are very confident of the answer. I then go over each statement and they learn a bit about each disease or statement. They were also read a statement where they come across a lifeless body and are supposed to come up with a list of what they would look for to determine how the person died (they do this as small groups). The first day we stay in class all day.

During the rest of the week, the guest lecturers and activities fill the time along with lectures from me on Embryology, histology, cell/molecular cell biology and cancer biology. Among the guest speakers are Llyod Kennedy who talks about what a pathology assistant does and the process of an autopsy. At another time he does a brain dissection with them. I have someone from the KRCC usually a radiation therapist talk about what they do. I also had two genetic counselors talk for 30-45min each, one on several different types on hereditary disease and the other on hereditary breast cancer. We also have a tour of the Cancer Research lab, visit the Anatomy museum in Botterell Hall, the morgue, visit the anatomy museum and get a bit of a talk from the curator, and the pathology plastination museum

Here is how this year's course went

Monday AM	Introduction to pathology, Handout on medical terminology,
	PM etiology of diseases, handouts on causes of disease and "find a word", embryology lecture
Tuesday	AM Lecture on cell/molecular biology, lecture by Lori Van Manen on genetic counseling of hereditary breast cancer
	PM lecture by Ines Sumargo on genetic counseling of various genetic conditions, lecture by Lloyd Kennedy on path assistants and tour of the morgue
Wednesday	AM Model of DNA mutations, Visit to pathology plastinated museum talk by Jackie Gibbons on Radiation therapy
	PM Lecture on Cancer biology, Tour of Cancer Research Labs
Thursday	AM Brain dissection pathology suite by Lloyd Kennedy, finish lecture on cancer biology
	PM handouts on cancer, visit anatomy museum and talk by Wayne Lyons, go over answers to True/false statements given
Friday	AM Evaluations, lecture or discussion on topic of choice, finish answers to True/false statements, Give them the secret to staying healthy

## **QPAG Reunion, September 21,22, 2002**

The Second Queen's Pathology Departmental Reunion was held on a beautiful Sunday in late September. Coincidentally, the scheduling of the Reunion on September 21<sup>st</sup> and 22<sup>nd</sup> coincided almost exactly with the 40<sup>th</sup> anniversary of the official opening of the expansion of the Richardson Laboratory building from two stories to four.

The Reunion was held in parallel with the Ontario Association of Pathologists Meeting which was hosted in Kingston by a number of our faculty, led by David Hurlbut. Approximately 40 present and past members of the department attended the Reunion, one of the most senior of whom

was Dr. Egils Liepa, a retired pathologist from the Ottawa area who was last in the department in 1955 (the year in which the current Chair was born!!!). A banquet held on Saturday evening at the Senior Staff Mess of RMC, in association with the OAP, opened the festivities. As the moon rose over the lake, everyone had an opportunity to catch up with old friends and reminisce.

The initial part of the reunion program, held on Sunday, featured a celebration of some of the outstanding research accomplishments by departmental faculty during the last four or five decades. Roger Deeley began with a seminar entitled "Drug Pumps: In Sickness and in Health", in which he described the discoveries that Susan Cole's and his laboratories have made in understanding the function of multi-drug resistance proteins. Bob Kerbel, the first Director of the Cancer Research Group established by Nathan Kaufman in the mid-1970s, came to the Reunion from his current position as a Canada Research Chair in Molecular Medicine at Sunnybrook and Women's College Health Sciences Center to give a talk on "Chemotherapy and Cancer – Is Less, More? – An Angiogenic Perspective". Dr. Kerbel described his important work in converting an understanding of tumour angiogenesis into effective therapeutic interventions. David Lillicrap, in his seminar entitled "Genes for Blood-Clotting: Balance is the Key" illustrated how his work in the molecular pathogenesis of disorders of thrombosis is leading to potential gene therapies. Bob Kisilevsky concluded the morning's program with a life lesson: "If at First you Don't Succeed – Keep Trying". Bob took the audience from his initial studies on amyloidosis, done in collaboration with Michael Axelrad in the early 1970s, through his unraveling of the pathogenesis of AA amyloidosis, the resulting novel therapeutic approach to amyloidosis and the potential, unpredicted relevance of his work to atherosclerosis and the treatment of malaria! Bob's most remarkable achievement, though, was being able to deliver his entire seminar on a single overhead!!! (Take that, Powerpoint!) Molecular medicine was the theme that linked all these presentations. In each case, the presenters demonstrated how a detailed understanding of pathologic processes at a molecular level is setting the stage for precise tailored therapeutic interventions in a number of widely divergent diseases.

After a sumptuous buffet lunch on the lawn of the Queen's University Club, the group reconvened for a series of vignettes which highlighted initiatives and issues in the educational, clinical and administrative activities of the department. Sandy Boag in his talk "Up and Running with Online Digital Pathology Imaging at Queen's: Two Years, Ten Thousand Images and Still Counting", illustrated the great strides the department has recently made integrating digital technology into both clinical service and education. David Dexter, one of our numerous award winning teachers, highlighted a number of our department's teaching initiatives in his seminar "Advances in Pathology Education". In the final talk, called "Error Management in Diagnostic Pathology: Why You Need a 'System'", I highlighted the complexity involved in establishing an effective strategy to minimize error in laboratory medicine.

The Reunion was a terrific success and I would like to gratefully acknowledge the hard work of the organizing committee which was led by Paul Manley and included David Lillicrap, David Hurlbut, Sandy Boag and David Dexter. Special thanks also go to Barb Latimer for her invaluable administrative support and Lloyd Kennedy for excellent photography.

***UNDERGRADUATE, GRADUATE  
AND  
POSTGRADUATE  
EDUCATIONAL PROGRAMS***



## UNDERGRADUATE PROGRAMME

**Phase I Pathology** is given in the academic year from mid-November to mid-February to first year medical students. Enrolment was 100 for 2002-2003.

**Phase II Pathology** is given after Phase I to 2<sup>nd</sup> year medical students but not in a Pathological Unit as such, but rather as a course combined with many other disciplines. Enrolment was 92.

**Rehabilitation Medicine 225 (Winter 2003)** The Department of Pathology continues its involvement in the Pathology Unit of this course. The Unit, which runs for five hours, contains sections on Inflammation & Tissue Healing (Dr. P. Manley), Neoplasia (Dr. T. Childs), Disturbances of Growth and Development (Dr. D. Dexter) and Neuromuscular Tumours of the CNS (Dr. J. Rossiter). The Pathology section of the course is co-ordinated by Dr. Sandip SenGupta. 87 students were enrolled.

**Pathology 410** is a half credit course that runs concurrently with **Pathology 824B** in the Fall term and is co-ordinated by Dr. John Rossiter. It is offered to 4<sup>th</sup> year Life Sciences (non-medical) and graduate students. Forty-five undergraduate students enrolled in this course in 2002. Evaluation for undergraduate students includes a mid-term and final exam whereas graduate students, in addition to the exams, are expected to submit a term paper. A review of the course content, exams, marking system and student evaluations took place in March 2002 by the Co-ordinator and lecturers.

**Pathology 425** "Current Topics in Human Genetics" was offered for the first time in the Fall of 2002. It is a half credit course offered primarily to Life Science students and co-ordinated by Dr. Lois Mulligan. This course is taught by multiple instructors and includes lectures, student seminars and group discussions. Enrolment in 2002 was 11.

**Pathology 430** is a half-credit course that is offered concurrently with **Pathology 826** in alternate Winter terms. Drs. Robert Kisilevsky and David Lillcrap are Co-ordinators. Four diseases are covered in depth, examining the molecular events leading to the development of these disorders. Enrolment is limited to 12 with preference given to graduate students. Evaluation includes seminar presentations and written reports. Two undergraduate students enrolled in the Winter 2003 session.

**Pathology 499** is a one and a half credit thesis project course co-ordinated by Dr. David Lillcrap and Dr. Robert Kisilevsky. Department faculty members supervise students on a year-long thesis project. Evaluations include a draft thesis introduction, seminar presentation, project defence, laboratory work evaluation and a written thesis. This course was reviewed by the Life Sciences Program in preparation for the 2002-03 academic year. Uniform guidelines were then distributed to all participating departments. Enrolment is limited to approximately 12 students; 11 were enrolled in 2002-03.

**Life Sciences 422** is a half-credit, inter-disciplinary course offered through the Life Sciences Department in cellular / molecular neuroscience. The course is based on lectures and student seminars of selected readings. Sections are taught by faculty in Pathology (J. Rossiter), Physiology (K. Rose and G. Ross) and Anatomy & Cell Biology (C. Barajas-Lopez). Enrolment was 16.

## GRADUATE PROGRAMME

The Graduate Programme in the Department of Pathology is administered by the Graduate Programme Committee. The Committee consists of four members of the Department, one of whom is designated Co-ordinator, plus the Head of the Department (Dr. Iain Young) and two graduate student representatives *ex officio*. Dr. Peter Greer continued as Co-ordinator of the Program and Chair of the Department of Pathology Graduate Committee during 2002. Faculty members from January to June 2002 were Drs. David LeBrun, Lois Mulligan and Karen Harrison. Dr. Mulligan resigned from the Committee as of June 30 and was replaced by Dr. Leda Raptis. The student representatives until July 1, 2002 were Adina Vultur and Lee O'Brien. Ted Wright and Fiona Rawle assumed these positions for the 2002/2003 academic year. The Committee met on a monthly basis to make decisions on admissions; review student progress; discuss Comprehensive topics; review membership of Comprehensive, Master's and Doctoral examining committees; set stipend rates; and recommend students for scholarships and awards.

Twenty-seven students were registered during the 2002 calendar year. Registration was equally distributed between the Master's and PhD Programmes. Suzie Abu-Abed, Yotis Senis and Dawei Zhang, all doctoral students, defended their theses in 2002. PhD students who defended their comprehensive proposals were Bob St. Onge, Peter Truesdell and Kevin Weigl. Fiona Rawle was successful in the defence of her Mini-Master's theses and was promoted directly to the PhD Program.

Department of Pathology graduate students were very successful in competitive award competitions for the 2002/03 academic year. Ontario Graduate Scholarships were awarded to Brian Brown, Glenn MacLean (reverted), Fiona Rawle, Adina Vultur, and Julie Yome. Glen MacLean was awarded an NSERC Fellowship for two years and Deborah Greer continued in her second year of NSERC funding. The National Cancer Institute of Canada continued to fund Bob St. Onge. Suzan Abu-Abed continued to be funded by a Medical Research Council studentship until receiving her PhD degree in May 2002. An Ontario Graduate Scholarships in Science & Technology was awarded to Brian Brown (reverted). Kevin Weigl, Adina Vultur (reverted) and Angela Hui successfully competed for McLaughlin Scholarships. Ted Wright was funded by a US Army initiative. A tuition bursary was awarded to Joanna Wojcik to cover the difference between foreign and domestic tuition fees.

More than 100 graduate studies applications were distributed in 2002 either by mail or in person. Many more enquiries were received and dealt with through electronic mail. Twenty-three applications were received and processed resulting in 11 students being conditionally accepted; and of those, three new students were accepted into research programs by supervisors in 2002.

#### **RECRUITMENT INITIATIVES:**

The Department of Pathology is represented at the Life Sciences careers evening in January. Many 3rd and 4th year students indicate their interest in 4th year projects or graduate studies at this event. In addition, the Department has a limited budget to invite excellent students to visit the Department from other centres. The Department of Pathology Graduate Studentship Award continues to be available to compete for recruitment of exceptional candidates. Together, these initiatives have improved the profile of the Department of Pathology in the Life Sciences programme and recruitment for graduate studies.

#### **OUTREACH:**

During the past year, several outreach initiatives involving graduate students and Faculty members in the Department have continued. Some students as well as some members of the Department have been involved in a Cancer Conference presented to some of the local public schools. This programme is organized by faculty and students in the Departments of Oncology, Biochemistry and Pathology. In addition, interested graduate students have been involved as judges for the Frontenac Lennox & Addington Science Fair. The Department of Enrichment Studies offers a Pathology course for gifted high school students across Canada. These two one-week sessions run in April/May and offer high school students a good overview of Pathology. The course will be run again in 2003.

#### **GRADUATE STUDENT PRESENTATIONS:**

Graduate students were honoured by invitations to present their research at national/international conferences. These are outlined below:

##### Fiona Rawle

##### Brian Brown

Am. Society of Gene Therapy - poster  
Southern Ontario Gene Therapy Conf – poster

##### Ted Wright

Era of Hope, (Sponsored by Department of Defence, US Army) Orlando, Florida, September 25-28, 2002

“Hepatocyte Growth Factor Interaction with its Receptor, MET”



Brandy Hyndman, PhD Student

Fifth Annual Meeting for Basic & Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002

“Acetylation of the E2A Oncogenic Protein Enhances Its Association with Transcriptional Co-Activators”  
44<sup>th</sup> Annual Meeting of American Society of Hematology, Philadelphia, Pennsylvania, December 6-10, 2002  
“Recruitment of Acetyl-Transferase Transcriptional Co-Activators by the N-terminal Transcriptional Activation Domain of E2A Oncogenic Proteins Results in Acetylation of E2A Itself”

Adina Vultur

18<sup>th</sup> Annual Meeting on Oncogenes, Frederick, MD, 2002

“STAT3 Activation in Cells Expressing the Large Tumor Antigen of Simian Virus 40”

## **RESEARCH SEMINAR SERIES**

Invited Speakers

**Dr. Andrew Craig**

Postdoctoral Fellow, Cancer Research Laboratories, Queen's University

“Transgenic Mice Reveal Roles of Fps and Fer Kinases in Regulating Hematopoiesis, Inflammation and Immunity”

**Dr. John E. Dick**

Senior Scientist, Program in Cancer/Blood Research Institute, Hospital for Sick Children, Toronto, ON

“Unexpected Complexity of the Human Hematopoietic Stem Cell Compartment”

**Dr. Shelagh Mirski**

Research Associate, Cancer Research Laboratories, Queen's University

“Topoisomerase II Localization and Drug Sensitivity”

**Dr. Michel Tremblay**

Professor, Depts. Biochemistry & Oncology, McGill University, Montreal, PQ

“Positive and Negative Involvement of the Small Protein Tyrosine Phosphatases TC-PTP and PTP 1b in Signal Transduction”

**Dr. Donald Maurice**

Associate Professor, Departments of Pharmacology & Toxicology and Pathology, Queen's University

“A Sabbatical Success Story: Assessment of the Potential use of Phosphodiesterase 3 Inhibitors as Anti-Angiogenic Drugs”

**Dr. Katherine Wynne-Edwards,**

Professor, Department of Biology, Queen's University

“Primary Prevention of Breast Cancer: An Evolutionary Perspective”

**Dr. Trang Hoang**

Laboratory of Hemopoiesis and Leukemia, Clinical Research Institute of Montreal, PQ

“Opposing Functions of the SCL and E2A Transcription Factors in Leukemogenesis”

**Dr. G.E. Hannigan**

Laboratory of Medicine & Pathobiology, University of Toronto & Research Institute

The Hospital for Sick Children, Toronto, ON

“Regulation of Signalling by Integrin-linked Kinase and Associated Proteins”

**Dr. Waheed Sangrar**

Postdoctoral Fellow, Cancer Research Institute, Division of Cancer Biology & Genetics, Queen's University

“Abnormal Vascular Morphology & Physiology in Transgenic Mice Tissue – Specifically Expressing Gain-of-Function Fps/Fes”

**Dr. Anne-Marie Mes-Masson**

Centre de Recherche CHUM et Institute de Cancer de Montreal, Hopital Notre-Dame, Montreal

“Microarray Analysis of Gene Expression Mirrors the Biology of an Ovarian Cancer Model”

**Dr. Alan Legarde**

Ottawa Regional Cancer Centre, Ottawa, ON

“Genetic Predisposition and Susceptibility to Colon Cancer”

**Dr. Matt van de Rijn**

Stanford University, Stanford, CA USA

“Gene Expression Profiling and Comparative Genomic Hybridization Studies on Saromas Using Microarrays”

**Dr. Norman Iscove**

Ontario Cancer Institute

“Differential Gene Expression in Pure Hematopoietic Stem Cells and their Downstream Progeny”

**Dr. John Bell**

Senior Scientist, Ottawa Regional Cancer Centre

“Oncolytic Viruses as Cancer Therapeutics”

**Dr. M. Bhatia**

Scientist, Stem Cell Biology and Regenerative Medicine, Robarts Research Institute

“Characterization of Human Stem Cells Towards Regenerative Medicine”

### Graduate Student Presentations

**Fiona Grant**, Dr. Lillicrap's Lab

*The Mammalian Immune Response to Adenoviral Gene Therapy in the Treatment of Hemophilia A*

**Sarah Kinkley**, Dr. Kisilevsky's Lab

*Hot on the Trail of SAA*

**Joanna Wojcik**, Dr. Elliott's Lab

*Investigations into the Role of Src and Stat3 in the Transcriptional Regulation of HGF in Breast Cancer*

**Angela Hui**, Dr. Elliott's Lab

*Regulation by Extracellular Matrix Adhesion of Met Kinase Activity and Scattering in Mammary Carcinoma Cells*

**Julie Yome**, Dr. Mulligan's Lab

*MEN 2B - Unravelling the Molecular Mystery*

**Julie Shaw**, Dr. Mulligan's Lab

*MEN 2B - Unravelling the Molecular Mystery – An Inducible Model for RET Expression*

**Patrick Smith**, Dr. Anastasiades' Lab

*Examination of the Effects of N-Acylated Glucosamines on Articular Chondrocytes*

**Catherine Lin**, Dr. Petkovich's Lab

*Development of Transgenic Mice Over-expressing hCyp26A1*

**Jimson Wong**, Dr. Davey's Lab

*The Role of Fission Yeast Rqh1 Protein in the Suppression of Recombination of Stalled Replication Forks*

**Kevin Weigl**, Dr. Cole's Lab

*Topology Studies of the Human Multidrug Resistance Protein 1, MRP1*

**Donna Situ**, Dr. Cole's Lab

*Characterization of Charged Amino Acids in the Third Membrane Spanning Domain of MRP1 (ABCC1): Role in Substrate Specificity and Transport*

**Lee Fraser**, Dr. Davey's Lab

*The Role of Uve1 in Eukaryotic Excision Repair*

**Peter Truesdell**, Dr. Greer's Lab

*Does the fps/fes Proto-oncogene Regulate Murine Mammary Development and Tumorigenesis?*

**Brian Brown**, Dr. Lillibrap's Lab

*Turning Foes into Friends: The Development of Viral Vector Systems for the Treatment of Hemophilia A*

### **COUNCIL OF ONTARIO UNIVERSITIES PERIODIC APPRAISAL**

Periodic appraisals of the graduate programs are undertaken at seven year intervals by the Ontario Council on Graduate Studies. A detailed brief, outlining all aspects of the Graduate Programme in the Department was prepared and submitted to the School of Graduate Studies and Research in May 1996, for final submission to the Council of Ontario Universities. In February 1997, the Department was informed that the Appraisals Committee had approved the MSc/PhD Programme in Pathology with an "A" rating. The Program is preparing for its next accreditation in 2003.

### **GRADUATE COURSES**

The following graduate courses are offered in the Department of Pathology:

A proposal was submitted to the Graduate School in 2002 to split the existing cancer biology course (Path 823) into two courses. One course would focus on Cancer Biology (based on the existing course) while the other would be a

course on experimental cancer diagnostics and therapeutics. These changes were approved by the School of Graduate Studies for the 2002/03 academic year.

### **Cancer Biology – Pathology 822**

Dr. Bruce Elliott is co-ordinating this new course. It will not be offered until the 2003/04 academic year.

### **Cancer Biology - Pathology 823**

This course is co-ordinated by Dr. Bruce Elliott. Essential questions in clinical and basic oncology are introduced and discussed. The course is offered in alternate years. Enrolment is limited to 20 students or less. It was offered in the 2002/2003 academic year; enrolment was 17.

### **Graduate Pathology for Non-Medical Students - Pathology 824**

The course co-ordinator is Dr. John Rossiter. This course provides a general introduction to the pathological processes involved in common human disease. This course is offered in conjunction with **Pathology 410** annually in the Fall. One graduate student was enrolled in the Fall term of 2002.

### **Human Genetics - Pathology 825**

The course co-ordinator is Dr. Lois Mulligan. Molecular mechanisms responsible for human disease are discussed with examples of diagnostic studies. The course is offered in alternate years in the Winter term. In the Winter of 2001-2002, seven students were enrolled.

### **The Molecular Basis of Disease - Pathology 826**

The course co-ordinators are Drs. Robert Kisilevsky and David Lillicrap. This graduate course is offered concurrently with **Pathology 430** in alternate years; enrolment is limited to 15 students or less. The course reviews in detail the pathogenic details of four specific areas of tumour disease. The course was offered in the Winter term 2002-2003. Five graduate students were enrolled.

Student Name	Program	Start Date	Supervisor	
<b>Abu-Abed, Suzan</b> 331 7803	PhD	09/98	Dr. Petkovich	Completed PhD 31/5/02
<b>Almquist, Kurt</b> 286 9464	PhD	09/95	Drs. Cole/Deeley	Became active/part time 9/02
<b>Brown, Brian</b> 413 2518	PhD	09/00	Dr. Lillicrap	
<b>Clarke, Fraser *</b> 477 0558	MSc	09/02	Dr. Petkovich	
<b>Davidson, Chris</b> 393 4600	PhD	09/97	Dr. Kisilevsky	Withdrew 09/02
<b>Dore, Naomi *</b> 398 9592	MSc	09/02	Dr. Cole	
<b>Fraser, Lee</b> 290 2264	PhD	09/98	Dr. Davey	
<b>Greer, Deborah</b> 350 2169	PhD	09/00	Dr. Davey	
<b>Grant, Fiona</b> 449 1856	PhD	05/02	Dr. Lillicrap	Mini-MSc 23/04/02
<b>Hui, Angela</b> 388 5490	MSc	09/01	Dr. Elliott	
<b>Hyndman, Brandy</b> 432 8795	PhD	05/01	Dr. LeBrun	
<b>Kang, Martin</b> 434 2041	MSc	09/99	Dr. Davey	
<b>Kinkley, Sarah</b> 433 4747	MSc	09/00	Dr. Kisilevsky	
<b>Lin, Catherine</b> 366 8934	MSc	09/01	Dr. Petkovich	
<b>MacLean, Glenn</b> 426 5917	PhD	09/99	Dr. Petkovich	
<b>O'Brien, Lee</b> 437 6344	PhD	09/00	Dr. Lillicrap	
<b>St. Onge, Bob</b> 403 9030	PhD	9/99	Dr. Davey	Defended Comps 04/03/02
<b>Senis, Yotis</b> 286 2703	PhD	05/96	Dr. Greer	Defended 11/07/02
<b>Shaw, Julie</b> 394 1113	MSc	09/01	Dr. Mulligan	
<b>Situ, Donna</b> 394 3477	MSc	09/01	Dr. Cole	
<b>Smith, Patrick</b> 399 1554	MSc	09/01	Drs. Greer/Anatassiades	
<b>Truesdell, Peter</b> 289 6434	PhD	09/99	Dr. Greer	Defended Comps 28/02/02
<b>Vultur, Adina</b> 366 6180	PhD	09/00	Dr. Raptis	
<b>Weigl, Kevin</b> 402 2721	PhD	09/99	Dr. Cole	Defended Comps 15/03/02
<b>Wojcik, Joanna</b> 458 2262	MSc	09/01	Dr. Elliott	
<b>Wong, Jimson</b> 399 8724	MSc	09/01	Dr. Davey	
<b>Wright, Ted</b> 404 5468	PhD	09/01	Dr. Elliott	
<b>Yome, Julie</b> 459 8727	MSc	09/01	Dr. Mulligan	
<b>Zhang, Dawei</b> 405 3380	PhD	09/98	Dr. Deeley	

\* New Students for 02/03

## **POSTGRADUATE MEDICAL EDUCATION**

Dr. Caroline Rowlands is the Director of the Postgraduate Education Programme in the Department of Pathology and also the Programme Director of Anatomical and General Pathology. Dr. John Rossiter is the Programme Director of Neuropathology. The Programme Director of Hematopathology is Dr. Dilys Rapson.

### **Resident Appointments**

#### **July 1, 2001-June 30, 2002**

Dr. Tim Childs	PGY-5
Dr. Patricia Farmer	PGY-3
Dr. Benjamin Mathew	PGY-1 (withdrew from the program)
Dr. Jason Sack	PGY-5

#### **July 1, 2002-June 30, 2003**

Dr. Patricia Farmer	PGY-4
---------------------	-------

### **AWARDS**

## **LECTURES/PRESENTATIONS**

### **Tim Childs**

- 1) "Malignant Melanoma: An Update", Pathology Grand Rounds, January 10, 2002.

### **Patricia Farmer**

- 1) "Vascular Pathology", Pathology Grand Rounds, June 27, 2002.
- 2) "Laboratory Diagnosis of Hemoglobinopathies", Pathology Grand Rounds, October 10, 2002.

### **Jason Sack**

- 1) "Closing Remarks", Pathology Grand Rounds, May 23, 2002.

## **ACCREDITATION - ROYAL COLLEGE OF PHYSICIANS AND SURGEONS**

The Royal College of Physicians and Surgeons Accreditation of the Anatomical Pathology, General Pathology, Hematopathology and Neuropathology Postgraduate Programs took place in October 1999. RCPS accreditation status for the Queen's Pathology programs is as follows: AP - full approval; GP - inactive; HP - inactive; NP - inactive. The inactive designation reflects that at the time of the survey no residents were registered in these programs. An internal review of the Hematopathology and Neuropathology programs was held in April 2002 and of the Anatomic Pathology Program in December 2002.

## **CANADIAN RESIDENT MATCHING SYSTEM (CaRMS)**

We did not match anyone in the 2002 CaRMS match. Out of the 12 candidates we interviewed, 2 withdrew, 2 went to other disciplines and 8 went to Laboratory Medicine, but with one exception, to their home Universities. The good news is that the majority of the candidates were genuinely interested in Pathology. This does reinforce the need to increase our profile in our own medical school, which we have already started to do more, and to continue to extend invitations to medical students at every opportunity, to spend some time in the Pathology department, to see exactly what we do. We made the decision not to enter the second iteration and to give the position to another program, rather than have a reluctant resident.

Foreign medical graduates can still enter through the International Medical Graduates program and there may be a new program where FMGs can apply to have their credentials assessed and then spend time in the program.

There is a new program (APIMG) whereby pathologists trained in their home country meet with and are assessed by Ontario Program Directors in a mini-Royal College exam-type process. If selected applicants then move on to a six month assessment process. If they pass this six-month placement they are eligible to write the RC exams within 5 years and must then work in an under serviced area in Canada. Dr. Victoria Muniz was one of these candidates from November 1<sup>st</sup> for a 6 month period. She was a trained pathologist in her home country of Argentina. Our Program received \$25,000 from the Ontario Government for her training.

	AGENCY	AMOUNT/YR	DURATION	TITLE OF RESEARCH PROJECT
. Deeley	CIHR	\$182,525	2001-2006	Investigations of MRP-Mediated Drug Resist Xenobiotic Transport
R. Deeley	Eli Lilly	\$67,000		Contract: Molecular Mechanisms of Resistanc Product and Platinum-Containing Drugs
Deeley & M. Petkovich	NCIC (Program Project Core)	\$67,098	2000-2003	Molecular Mechanisms of Drug Resistance
	NCIC	\$170,558	2000-2003	Investigations of Topoisomerase II in Drug R
ole et al	CIHR	\$100,000		Training Grant in Proteomics
	Proctor & Gamble, USA	\$43,470	2001-2002	Contract
	ODRA/OIT	\$124,866	2002	Infrastructure
Cole and 8 others	CIHR	\$113,679		Multi-user Equipment/maintenance grant
. Heaton, M. Raymond, A. Morales &	KGH, Hospital Research Grant	\$9,855		Free Testosterone: Which Method Provides Correlation?
J. van Eyk, R. Brison, C. Collier, D.	MOH & Long- Term Care: Emergency Health Services Research Grant	\$43,900	2000-2002	Novel Troponin I modification products as pr cardiac events in emergency patients.
n, C. Collier and M. Raymond	Pathology Clinical Trust Fund	\$5,880		False Negative Rate of Serum Protein Electr Screening for Idiopathic Peripheral Neuropat
: S. Cole	NCIC	\$204,610	2000-2003	Multidrug resistance conferred by MRP
. Flynn and 10 others	CFI/OIT/Industry in Kind	\$1,792,513	2000-2005	Protein Function Discovery
. Pater & 8 others	OIT	\$4,700,000		Queen's Cancer Research Institute
14 others	CIHR	\$47,640	2001-2004	Maintenance of Fluorescence Activated Cell Confocal Microscope: A Multi-User Facility
	CIHR	\$63,593	1999-2002	Role of HGF and the cell adhesion complex i metastasis of lung carcinoma.
		\$7,949	2002-2003	Terminal Award
	Faculty of Health Sciences, Queen's	\$10,000		Bridge Funding
	Pathology, Queen's	\$17,000		Interim Funding
doctoral Fellowship for new	USA/MRMC	\$19,732		Signal transduction in regulation of autocrin in cancer metastasis.
studentship for T. Wright)	USA/MRMC	\$22,935		Identification of hepatocyte growth factor aut breast carcinomas: Possible targets for therap
	Genentech (Contract)	\$5,000	2001-2002	Development of peptide antagonists to hepat as a novel approach to therapeutic interventio cancer.
	Pathology Clinical Trust	\$10,000	2002-2003	Gene Expression Profiling studies in Prostate
	NCIC	\$150,000	2001-2006	A molecular and genetic analysis of the <i>fps</i> p
	CIHR	\$127,873	2001-2004	A molecular and genetic analysis of the <i>muri</i>
& L. Mulligan	NCIC	\$45,445	2001-2004	Investigating Functional Differences Between Isoforms in Cell Growth and Development
: L. Mulligan	CIHR	\$135,612	2001-2004	Investigating Functional Differences Between Isoforms in Cell Growth and Development
nd P. Greer	Queen's University	\$414,000		Transgenic Mouse Barrier Facility

	AGENCY	AMOUNT/YR	DURATION	TITLE OF RESEARCH PROJECT
	Pathology Clinical Trust Fund	\$9,630	2001-2002	Genetic Studies of Sirenomelia and Holopros
et al	OAML	\$34,907		Molecular Cytogenetic Evaluation of Subtle 1 High Resolution Fiber FISH
& W. Paterson	ACG Clinical Research Fund	\$28,836	2000-present	Mast Cells in Gastroesophageal Reflux Disea
ow, G. Evans, W. Wobeser, K. Suh	Bayer Inc., Pharmacia Canada, Bristol-Myers Squibb Canada Inc., Queen's Work Study Pr.	\$33,228		Genetic Characterization of S. Aureus Isolate Blood
ow	Alexon-Trend/Remel Inc.	\$2,000		Feasibility Study of an Enzyme Immunoassay of D. Fragilis
y & W. Szarek	Inst. for Study of Aging, USA	\$120,000	2000-2002	Novel glycosaminoglycan precursors as anti-
y, W. Szarek and J. Kennedy	Bill & Melinda Gates Foundation	\$255,000	2000-2003	A novel approach to anti-malarial therapy.
/	CIHR	\$159,000	2001-2006	Amyloidogenesis: An Analysis of the Causal Experimental Murine Model
y & T. Tam	HSFO	\$65,000		Acute Phase SAA and Cholesterol Metabolis Inflammation
id R. Kisilevsky	RMC Research Fund	\$100,000		Protease Mediated Drug Delivery
	CRS	\$114,000	2001-2003	Transcriptional Repression of AML1/RUNX Leukemogenic Transcription Factor E2a-PB>
J. Matthews & L. Shepherd	KGH Clinical Research Grant	\$9,293	2001-2002	Development of a New Blood test to Assist in Lymphoproliferative Disorders
	CIHR/MRC	\$277,920	2000-2003	Elucidation of Protein-Protein Interactions In terminus of E2a
	MRC/CIHR	104,119	1998-2002	Characterization of Mechanisms Regulating Expression of Coagulation Factor IX
	LCDC	\$150,000	2000-2003	A National Hemophilia Mutation Testing Pro
	Canadian Hemophilia Society	\$50,000	1999-2001	Evaluation of a Model System for the Site-Sp of Hemophilic Mutations
	HSFO	\$88,944	2000-2005	Influence of Genotype and Environment on E Expression of vonWillebrand Factor
	CIHR	\$80,908	2000-2004	The molecular genetic basis of type 1 von Wi
	Bayer/CBS Partnership Fund	\$86,379	2000-2002	Inhibitor development following factor VIII & Evaluation of a mouse model
, M. Nesheim, M. Koschinsky, G. and D. Lee	Heart and Stroke Foundation of Ontario	\$112,200	2000-2005	Collaborative studies of hemostasis, fibrinoly cell growth and function"
	Ipsen Inc.	\$189,004	2001-2002	In vivo Studies in Hemostatic Efficacy and S: Recombinant Porcine Factor VIII Concentrat
	<b>HSFO</b>	<b>\$53,500/yr</b>	<b>5 years</b>	<b>Career Investigator Award</b>
	Bayer Inc.	\$192,458	2001-2002	Hemostatic Effects of a Liposomal Preparatic Recombinant Factor VIII Product, Kogenate
	National Centres of Excellence	\$76,000		Stem Cell Therapies for Hemophilia A
	Avigen Inc.	\$96,000		Recombinant AAV-mediated Gene Therapy 1



	AGENCY	AMOUNT/YR	DURATION	TITLE OF RESEARCH PROJECT
	CIHR	\$170,467		Gene Therapy for Hemophilia A: Studies of Host Immune Response
	Bayer/CBS Partnership Fund	\$72,500		Evaluation of a DNA Microarray-based Strat Determination in Hemophilia
	NCIC Contract	\$54,000	1992-present	Collection, Verification and Dissemination o of Study Material
& 10 others	CIHR	\$300,000		QU Transdisciplinary Training Program in C
& P. Greer	NCIC	\$45,445		Investigating Functional Differences between Isoforms in Cell Growth and Development
& P. Greer	CIHR	\$136,802		Investigating Functional Differences between Isoforms in Cell Growth and Development
	SWEP, Queen's	\$7,380		Pathology Research Assistant – Cancer Gene
& D. Rapson	BioMerieux	\$800,000		Waveform Analysis of the aPTT in Critically Patients
& D. Rapson	Can. Intensive Care Foundation	\$20,000		The Relationship between Insulin Resistance Inflammation and Clinical Outcomes
s and A. Morales	Diagnocare Inc.	\$		Evaluation of Urine Based Marker for Transi Carcinoma
S. SenGupta, W. Hanna, E. Sterns.	Canadian Breast Cancer Research Initiative	\$56,576		Steroid receptor content of benign breast epit cancer risk
1 & K. Aronson	KGH Clare Nelson Bequest	\$8,906		Breast Cancer Risk in Relation in HER-2/neu Expression and Exposure to Oral Contracept
1 & K. Aronson	Pathology Clinical Trust	\$6,608		Breast Cancer Risk in Relation in HER-2/neu Expression and Exposure to Oral Contracept
l, K. Pritchard, P. Watson, M. Pollack	NCIC	\$54,320		Clinical Trials Group "A Tumour, Tissue, an Bank for Breast Cancer Patients Participating Clinical Trials"
l, T. Whelan, et al	CBCRI	\$300,000	1999-2002	Clinical Trials Group "A Randomized Trial Radiotherapy in Early Breast Cancer"
l, K. Pritchard, et al	CBCRI	\$122,939	1999-2002	The Role of Neu/Erb B-2 as a Predictive Fact Response to Adjuvant Chemotherapy and Ta
l, J. Pater, et al	NCIC	\$3,761,902	1999-2004	NCIC Clinical Trials Group
	Parmacia & Upjohn	\$497,233	2000-2005	A Phase III Adjuvant Trial of Sequenced EC by Taxol vs. Sequenced AC followed by Taxo Therapy for Premenopausal Women and Post Women less than 60 years of age who have h Curative Surgery for Node Positive or High F Negative Breast Cancer
	Bristol Myers,	\$416,666		
	Squibb Ortho	Just Drug		
	Biotech	\$525,000		
	Amgen	\$525,000		
l and J. Pater	NCI US	\$1,136,984		NCI US Intergroup Award
	Berlex Canada Inc.	\$195,832		A Phase II Study of Oral Fludarabine Phosph with Previously Untreated Chronic Lymphoc
	KGH Foundation	\$8,724	2001-2002	Development of a Method for the Study of M Patterns of the Human Genome
	Pathology Clinical Trust Fund	\$9,630	2001-2002	Genetic Studies of Sirenomelia and Holopros
	Health Canada	\$1,500		National MRSA Surveillance Project
, M. Loeb, A. McGeer and A. Simon	US DHHS	\$239,000		Implementation and assessment of a Diagnos Algorithm for Urinary Tract Infections in Lo

	<b>AGENCY</b>	<b>AMOUNT/YR</b>	<b>DURATION</b>	<b>TITLE OF RESEARCH PROJECT</b>
				Facilities
& D. Hunter	Gov. of Canada, Dept. of National Defense	\$438,358		Health Outcomes Study
	Pathology Clinical Trust	\$10,000		Impact of Prescriber Information Feedback o Resistance Utilization at St. Mary's of the La
	Bristol Myers Squibb Clinical Research	\$9,000/case		Multicenter Randomized Controlled Trial of Treatment of Intra-Abdominal Infection
	Health Canada	\$35,000		Resources for Infection Control in Hospitals
	Health Canada	\$25,000		Canadian Surgical Wound Infection Surveill:
(Infection Prevention Activities)	CIDA	\$2,043,420	2001-2004	Strengthening Essential Public Health in the
, M. Louie A. Simor	PSI Foundation	\$85,440		Household Transmission of Methicillin Resis
, L. Johnston	Health Canada	\$20,490		Mortality of Nosocomial Pneumonia in Cana Centers
	Health Canada	\$50,000		Canadian Surgical Wound Infection Surveill:

**DEPARTMENT OF PATHOLOGY  
VISITING LECTURERS  
2002**

**VISITING LECTURERS  
2002**

**INVITED SPEAKERS**

<b>NAME</b>	<b>TITLE</b>	<b>DATE</b>
<b>Dr. Janet Rossant</b> Joint Head, Program in development and Fetal Health at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto and Professor, Departments of Molecular and Medical Genetics/Obstetrics/Gynecology, University of Toronto	Signalling Pathways in Early Mouse Development (The Second Nathan Kaufman Visiting Lecturer)	January 10, 2002
<b>Dr. Phillip Isotalo</b> Resident, Mayo Clinic, Rochester, NY	Histopathologic and In Situ Hybridization Identification of Fungal Organisms	January 17, 2002
<b>Dr. John E. Dick</b> Senior Scientist, Program in Cancer/Blood Research, Hospital for Sick Children	Unexpected Complexity of the Human Hematopoietic Stem Cell Compartment	January 15, 2002
<b>Dr. John Veinot</b> Associate Professor, Pathology & Laboratory Medicine, University of Ottawa and Ottawa Heart Institute	Cardiomyopathies: Practical Consideration	January 24, 2002
<b>Dr. Michel Tremblay</b> Professor, Departments of Biochemistry and Oncology, McGill University	Positive and Negative Involvement of the Small Protein Tyrosine Phosphatases TC-PTP and PTP1b in Signal Transduction	February 5, 2002
<b>Dr. Donald Maurice</b> Associate Professor, Departments of pharmacology & Toxicology and Pathology, Queen's University	A Sabbatical Success Story: Assessment of the Potential Use of Phosphodiesterase 3 Inhibitors as Anti-Angiogenic Drugs	February 19, 2002
<b>Dr. Katherine Wynne-Edwards</b> Professor, Department of Biology, Queen's University	Primary Prevention of Breast Cancer: an Evolutionary Perspective	February 26, 2002
<b>Dr. G.E. Hannigan</b> Laboratory of Medicine & Pathobiology, University of Toronto and Research Institute, Hospital for Sick Children, Toronto, ON	Regulation of Signalling by Integrin Linked Kinase and Associated Proteins	March 20, 2002
<b>Dr. Anne-Marie Mes-Masson</b> Centre de Recherche CHUM et Institute de Cancer de Montreal Hopital Notre-Dame, Montreal	Microarray Analysis of Gene Expression Mirrors the Biology of an Ovarian Cancer Model	April 23, 2002
<b>Mr. Kevin Varley</b> Summer Student, Department of Pathology, Queen's University	History of pathology: Rudolph Virchow	July 25, 2002.
<b>Dr. Margaret Hough</b> Assistant Professor, Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, ON	Lymphomagenesis in HOX11 Transgenic Mice	July 30, 2002.
<b>Ms. Iris Teo</b> Summer Student, Department of Pathology, Queen's University	The Physiology of Pain	August 1, 2002

<b>Dr. M. Bhatia</b> Scientist, Stem Cell Biology and Regenerative Medicine, Robarts Research Institute	Characterization of Human Stem Cells Towards Regenerative Medicine	September 17, 2002
<b>Dr. John Bell</b> Senior Scientist, Ottawa Regional Cancer Centre, Ottawa, ON	Oncolytic Viruses as Cancer Therapeutics	October 1, 2002
<b>Dr. Norman Iscove</b> Ontario Cancer Institute	Differential Gene Expression in Pure Hematopoietic Stem Cells and Their Downstream Progeny	October 22, 2002
<b>Dr. Alain Legarde</b> Ottawa Regional Cancer Centre	Genetic Predisposition and Susceptibility to Colon Cancer	November 5, 2002
<b>Dr. Shannon Bard</b> American Liver Foundation Postdoctoral Fellow, Tufts University School of Medicine, Department of Physiology	“Resistance is Futile, Prepare to be Inhibited. Multitoxin Resistance in Fish Exposed to Pollutants is Associated with P-Glycoprotein Activity	December 16, 2002
<b>Dr. Matt van de Rijn</b> Stanford University	Gene Expression Profiling and Comparative Genomic Hybridization Studies on Sarcomas using Microarrays	November 1, 2002

**SENIOR STAFF  
DEPARTMENT OF PATHOLOGY  
AND QUEEN'S UNIVERSITY  
LECTURES**

**SENIOR STAFF  
QUEEN'S UNIVERSITY AND KGH  
LECTURES**

*Dr. S. Boag*

- 1) "The Science of the LAM's" or "The Lymphangiomyomatosis (LAM) 0 Angiomyolipoma (AML) Connection: Masoicismor Metastasis?", Pathology Grand Rounds, May 9, 2002.

**Dr. C. Collier**

- 1) Teaching and Presentation Skills – Department of Psychiatry, Queen's University, September 4, 2002.
- 2) "Biological Individuality and Reference Values", Pathology Grand Rounds, October 3, 2002.
- 3) "Fostering Life-Long Learning Skills", Faculty Development School of Medicine, November 2002
- 4) MICR 809/909 "Communications Skills for the 21<sup>st</sup> Century", November 2002
- 5) BCHM-441 "Application of biochemistry in a Clinical Chemistry Lab", November 2002

*Dr. D. Dexter*

- 1) "Deaths in Custody: A Kingston Perspective", Pathology Grand Rounds, September 5, 2002.

*Dr. H. Feilotter*

- 1) "Prostate Tumour Profiling: a Pilot Study" (Tomorrow's Technology on Yesterday's Samples), Pathology Grand Rounds, May 2, 2002.

**Dr. P. Greer**

- 1) Kingston Regional Cancer Centre, KGH, 2002.

**Dr. K. Harrison**

- 1) "Molecular Cytogenetic Analysis of Subtle Chromosome Rearrangements: A Cytogeneticist's FISH'ing Tales", Pathology Grand Rounds, February 14, 2002.
- 2) "Genetic Changes Associated with Oligodendrogliomas: 1p/19q Deletions", Pathology Grand Rounds, December 12, 2002.

**Dr. D. Hurlbut**

- 1) Pathology Enrichment Course for High School Students, "Forensic Pathology", May 9, 2002.
- 2) "Hepatic Fibrosis: Pathogenesis and Clinical Implications", Pathology Grand Rounds, November 7, 2002.

*Dr. P. Isotalo*

- 1) "Pot-Pourri of Pathology: Case Presentation", Pathology Grand Rounds, November 14, 2002.

*Dr. T. Karnauchow*

- 1) "Antigen Detection in Diagnostic Virology", Pathology Grand Rounds, June 13, 2002.

**Dr. R. Kisilevsky**

- 1) "Cholesterol Mobilization from Macrophages at site of Tissue Injury", Pathology Grand Rounds, November 28, 2002.

**Dr. D. LeBrun**

- 1) "Chromatin Alteration in Gene Regulation and Cancer", Pathology Grand Rounds, October 24, 2002.

**Dr. D. Lillicrap**

- 1) Department of Physiology, Queen's, "Genetic Influences on the Initial Phase of Hemostasis: A Delicate Balance", January 21, 2002.
- 2) Pediatric Grand Rounds, Queen's University, "The Role of VWF in Disorders of Hemostasis", January 5, 2002.
- 3) "von Willebrand Factor: Size Does Matter", Pathology Grand Rounds, March 28, 2002.
- 4) "Hemophilia B: A Paradigm for the Application of Gene-Based Medicine, Genetics Grand Rounds, November 27, 2002.

**Dr. P. Manley**

- 1) "Helicobacter Pylori: Inflammation to Malignancy", Pathology Grand Rounds, September 12, 2002..

*Dr. L. Mulligan*

- 1) "The Genetics of Hirschsprung Disease: Many Paths to a Single End", Genetics Grand Rounds, January 30, 2002.

**Dr. D. Rapson**

- 1) "Conformational Thrombophilia: A Link with CJD and Alzheimer's Disease, Pathology Grand Rounds, April 4, 2002.

**Dr. J. Rossiter**

- 1) "Parkinson's Disease: The Role of the Ubiquitin-Proteasome System", Pathology Grand Rounds, February 7, 2002.

**Dr. C. Rowlands**

- 1) "What Have Toads got to do with It?", Pathology Grand Rounds, February 28, 2002.
- 2) "The Pap Smear in 2002", Pathology Grand Rounds, December 5, 2002.

**Dr. S. SenGupta**

- 1) "An External Quality Assurance Program for Surgical Pathology: Overview of the Proposed QMP-LS Model", Pathology Grand Rounds, January 31, 2002.
- 2) "An External Quality Assurance Program for Surgical Pathology: Overview of the Proposed QMP-LS Model", Pathology Grand Rounds, March 7, 2002.

**Dr. L. Shepherd**

- 1) "ASCO 2002: What's Neu", Pathology Grand Rounds, May 30, 2002.

**Dr. S. Taylor**

- 1) "Teaching in Genetics – Take Charge Again", Pathology Grand Rounds, April 11, 2002.

*Dr. Lewis Tomalty*

- 1) "Bioterrorism: What are the Issues 6 Months Later?", Pathology Grand Rounds, April 25, 2002.

*Dr. I. Young*

- 1) "Update on Departmental Imaging Resources", Pathology Grand Rounds, June 6, 2002 (co-presenters: Lloyd Kennedy, Kevin Kell and Troy Feener).

**Dr. D. Zoutman**

- 1) "Antibiotics n Moderation: Results of the 'Aim' Pilot Project in Kingston", Pathology Grand Rounds, October 31, 2002.



**INVITED LECTURES OUTSIDE OF QUEEN'S AND KGH  
SENIOR STAFF  
DEPARTMENT OF PATHOLOGY**

**Dr. S. Cole**

- 1) CSBMCB 45th Annual Meeting and 12th Winternational Symposium on "Membrane Proteins: Implications for Therapeutics", Banff, AB, March 24, 2002.
- 2) American Association for Cancer Research (AACR) 93rd Annual Meeting, San Francisco, CA, April 8, 2002.
- 3) Symposium, on "Advances in Understanding Transport of Drugs and Toxicants", ASPET, Annual Meeting of the Societies of Experimental Biology, New Orleans, LA, April 23, 2002.
- 4) Symposium, on "The Role of Transporters in Drug Metabolism", IUPHAR, XIVth International Congress of Pharmacology, San Francisco, CA, July, 2002.
- 5) 22nd International Symposium "Xenobiotics and Host Responses" of the University of Occupational and Environmental Health, Kitakyushu, Japan, September 24, 2002.
- 6) Dept. of Biology, McMaster University, Hamilton, Ontario, January 31, 2002.
- 7) Dept. of Pharmacology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, February 11, 2002.
- 8) Eli Lilly Pharmaceutical Company, Indianapolis, IN, February 15, 2002 (with R. Deeley)
- 9) Dept. of Biochemistry, National University of Singapore, September 16-17, 2002.
- 10) Dept. of Surgery, Shinshu University School of Medicine, Matsumoto, Japan, September 20, 2002.

**Dr. C. Collier**

- 1) Association of Clinical Biochemists Education Workshop, Glasgow, Scotland, May 2002

**Dr. R. Deeley**

- 1) Eli-Lily Pharmaceuticals, Indianapolis, February 2002.
- 2) Cancer Care Nova Scotia Videoconferencing Oncology Grand Rounds, Capital Health, Halifax NS, May 2002.
- 3) Departments of Microbiology & Immunology, Dalhousie University, Halifax, NS, May 2002.

**Dr. D. Dexter**

- 1) Ontario Association of Pathologists Annual Meeting, "Deaths in Custody", Kingston, ON, September 2002.

*Dr. P. Greer*

- 1) Department of Biology, McMaster University, 2002.
- 2) Department of Immunology, University of Calgary, 2002.
- 3) Department of Biochemistry, University of Western Ontario, 2002.

**Dr. K. Harrison**

- 1) Clinical Applications of FISH, Michener Institute, April 22, 2002.

**Dr. D. Hurlbut**

- 1) Grade 5 public school class, "Les Systemes du Corps", Mgr – Remi-Gaulin, Kingston, February 2002.

**Dr. T. Karnauchow**

- 1) "Antibiotic Resistance in Clinically Significant Bacterial Isolates at KGH". Third Annual Eastern Ontario Regional Infectious Diseases and Medical Microbiology Conference. Montebello, QC, October 21, 2002.

**Dr. M. Khalifa**

- 1) Saudi Bio, Juddah, Kingdom of Saudi Arabia, "Human Genome Project".
- 2) Visiting Professor, King Faisal Hospital & Research Institute, Saudi Arabia.

**Dr. R. Kisilevsky**

- 1) Department of Experimental Pathology, University of Cagliari, Cagliari, Sardinia, Italy, "The Biochemistry of In-vivo Amyloidogenesis and Strategies for its Prevention" and "The Mobilization of Cholesterol Released at Sites of Tissue Injury", March 2002.

- 2) Department of Biochemistry, University of Oslo, Oslo, Norway, "The Biochemistry of In-vivo Amyloidogenesis and Strategies for its Prevention" and "The Mobilization of Cholesterol Released at Sites of Tissue Injury: The Physiological Function of Serum Amyloid A 2.1?". March 2002.
- 3) Department of Biochemistry, University of Oporto, Amyloid Research Unit, Oporto, Portugal, "Acute Inflammation and the Physiological Role of the Major Acute-Phase Protein Serum Amyloid A 2.1", October 2002.
- 4) PROBUS CLUB of Kingston, Canada, "Alzheimer's and Diabetes: What do they have in common? What can we do about it?", A Public Lecture, November 2002.

**Dr. D. LeBrun**

- 1) Canadian Association of Pathologists Annual Meeting, "Chromosomal Translocation in Pediatric ALL Mechanisms of Leukemagenesis, June 2002.

**Dr. D. Lillicrap**

- 1) North Carolina Chapter of National Hemophilia Foundation, Greensboro, North Carolina, "History of Hemophilia: An overview", March 11, 2002.
- 2) TV Ontario: More to Life, Toronto, Ontario, "Bleeding Disorders- Treatment and Diagnosis", March 18, 2002.
- 3) Education and Research Day, Canadian Hemophilia Society, Ottawa, ON, "VWD: Current and future trends, genetic testing", April 6, 2002.
- 4) Canadian Hematology Society, Training Fellows Conference, Montreal, QC, "Genetic Diagnosis of Hemophilia", April 11, 2002.
- 5) National Hemophilia Foundation, 5th Gene Therapy Workshop, Philadelphia, USA, "Pre-clinical studies of helper-dependent adenoviral hemophilia gene therapy in mouse and dog models of hemophilia", April 12 & 13, 2002.
- 6) XII Annual Hemophilia Study Update, Rome, Italy, "Coagulation inhibitors as a complication of hemophilia gene therapy", April 20-22, 2002.
- 7) New York City Hemophilia Treatment Centre, New York, USA, "Laboratory monitoring of recombinant factor VIII therapy", June 13 & 14, 2002.
- 8) 27th Congress of the International Society of Blood Transfusion, Vancouver, BC, "Molecular Biology for Blood Bankers - Gene Expression", August 25, 2002.
- 9) European VWD Consortium Meeting, University of Sheffield, UK, "The Canadian Type 1 von Willebrand Disease Study", September 22, 2002.
- 10) University of Massachusetts Hemophilia Center, Worcester, Mass, USA, "Laboratory Assays for Recombinant Factor VIII ", October 10, 2002
- 11) Bayer/Canadian Blood Services Partnership Fund Conference, Montreal, QC, "Hemophilia Gene Therapy: How long is the Tunnel and How Bright is the Light?", October 15, 2002.
- 12) US National Hemophilia Foundation Annual Meeting, Florida, USA, "Pre-clinical studies of hemophilia gene therapy with Adeno-Associated and Helper-dependent adenoviral vectors", October 29, 2002.
- 13) The 25th Congress of the Japanese Society on Thrombosis and Hemostasis, Kobe, Japan, "Recent Progress in hemophilia gene therapy", November 13, 2002.

**Dr. S. Ludwin**

- 1) 7<sup>th</sup> European Congress of Neuropathology, Helsinki, Finland, "Angiogenesis of Multiple Sclerosis", July 14-17, 2002.
- 2) Keynote Speaker: "Inflammation, Demyelination and Axonal Loss: Insights from Pathology". 7<sup>th</sup> Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and 18<sup>th</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Baltimore, Maryland, September 18-21, 2002.
- 3) Invited Guest Lecturer: "Pathology and Pathogenesis in MS: Clinical and Experimental Studies" in the Symposium on Multiple Sclerosis at the 42<sup>nd</sup> Annual Meeting, Canadian Association of Neuropathologists, Vancouver, BC, October 2002.

**Dr. P. Manley**

- 1) University of Western Ontario and University of Toronto, "Alternate Funding Plans", September 2002.

**Dr. L. Mulligan**

- 1) MDS Fall Scientific Symposium, Toronto, ON, "Multiple Endocrine Neoplasia: clinical and Laboratory Diagnosis.
- 2) City Wide Endocrine Rounds, University of Toronto, "The View from RET: Dissecting Receptor Function and Dysfunction".

**Dr. D. Rapson**

- 1) International Society of Thrombosis and Hemostasis Scientific Sub Committee on DIC, Boston, MS, "Prospective Validation of the DIC Scoring System. An Analysis of its Application in a Cohort of Critically Ill Patients", July 19, 2002.

**Dr. S. SenGupta**

- 1) McMaster University, Department of Pathology, "Alternate Funding Plan at Queen's University".

**Dr. L. Shepherd**

- 1) OSMT, "The New WHO Classification of Myelodysplasia.
- 2) NCIC CTG Annual Spring Meeting, "The NCIC CTG Tumour/Tissue/Data Bank.

**Dr. L. Tomalty**

- 1) 8<sup>th</sup> Undergraduate Microbiology Education Conference in Orlando, "Using ASM Resources in Preparing Power Point Presentations".
- 2) Ontario Medical Education Network Video Conference, "Promoting Active Learning with Technology".

**Dr. D. Zoutman**

- 1) Romanow Commission on the Future of Health Care in Canada, "The Impact of Nosocomial Infections on the Canadian Health Care System", April 2002.
- 2) Community and Hospital Infection Control Association of Canada, Eastern Ontario Chapter, "Broad Spectrum Cephalosporinases, Genetics and Clinical Significance", Kingston, ON, January 30, 2002.
- 3) Medical Grand Rounds, Brockville General Hospital, "Antimicrobial Resistant Gram Negative Pathogens and Clinical Management Strategies", May 1, 2002.
- 4) Leeds Grenville Health Region, "Management of Hepatitis B", May 3, 2002.
- 5) University of western Ontario, Steiner Institute, "Impact of Modern Surveillance Methods for Infection Prevention", May 9-10, 2002.
- 6) St. Vincent de Paul Hospital, Medical Grand Rounds, "Epidemiology and Management of Sarcoptes Scabiei Infection", September 20, 2002.
- 7) Community and Hospital Infection Control Association of Canada, Ottawa Carlton Chapter, "Expanded Spectrum Beta-Lactamases: Significance and Management", November 8, 2002.
- 8) Ontario Hospital Association, "Resource Management and Infection Control in Canada", November 18, 2002.
- 9) International Quality and Patient Safety Congress, "Infection Prevention and Control Program Processes in Canada", November 27, 2002.

## **SENIOR STAFF COMMITTEES**



## SENIOR STAFF COMMITTEES

**Dr. S. Boag:** Member, Queen's Senate Committee on Information Technology; Chief of Service, Division of AP; Pathology Rep, Lung Tumour Board, KGH; Member, Pathology, Laboratory Information System Prioritization Group; Member, Pathology Quality and Utilization Improvement Committee.

**Dr. S. Cole:** Member, Board of Directors, PARTEQ Innovations, Queen's; Member, Nominating Committee, PARTEQ Innovations, Queen's; Member, Chancellor's Research Award Committee; Member, Microarray Laboratory Management Committee; Member, Advisory Research Committee, Subcommittee I; Member, Internal Academic Review Team (Biochemistry); Member, University Senate Agenda Committee; Member, University Senate; Member, Joint Board/Senate Committee to Select the Next Principal; Member, Scientific Management Committee, CFI Grant; Member, Research/Operation Subcommittee, PFD; Member, Pathology Haust Trust Fund Committee.

**Dr. C. Collier:** Member, Cross Faculty Teaching Forum Committee, Queen's; Member, Council on Employment Equity, Queen's; Block Coordinator, Phase IIA; Interviewer, Faculty Admissions Process; Presenter/Coordinator, TIPS, Queen's; Member, PBL Committee, Faculty of Health Sciences; Member, Faculty of Health Sciences Faculty Development Committee; Member, Search Committee for Pathology Head; Member, Pathology Staff Meetings; Member, Pathology Postgraduate Education Committee; Director, St. Lawrence College MLT Clinical Year Program; Member, Division of Clinical Laboratory Staff Meeting, KGH; Consultant Biochemist at BGH.

**Dr. R. Deeley:** Director, Cancer Research Laboratories/QCRI Division of Cancer Biology & Genetics; Co-Chair, Cancer Research Institute Fund Raising Committee; Member, Council of Basic Science Heads; Member, (Pathology) and Chair (Oncology) Promotions, Tenure and Reappointment Committee; Director Basic Oncology, KRCC; Member, Executive Committee, KRCC .

**Dr. D. Dexter:** Member, Student Progress and Promotion Committee, Queen's; Member, Nominating Committee, Faculty of Health Sciences, Queen's; Vice-President, Medical Staff, KGH; Member, Information Management Committee, KGH; Director, Point of Care Testing, HDH/KGH; Member, Ambulatory Clinics Committee, HDH; Founder/Member, Special Resources Committee, Le Royer Patrons, HDH; Member, Quality Improvement Committee of the Board, HDH; Member, E2 Regional Coordinating Committee; Member, ORLSP E2 Lab Physicians & Scientists Working Group; Member, MoCert for the RCPSC; Member, Pathology Finance Committee; Member, General Pathology Residency Program Committee; Member, Anatomic Pathology Residency Program Committee; Member, Hematopathology Residency Program Committee; Member, Pathology Consolidated Division of Hematopathology.

**Dr. B. Elliott:** Coordinator, Flow Cytometry and Confocal Microscope Facility; Member, Pathology Nathan Kaufman Visiting Lectureship Committee.

**Dr. A. Fletcher:** Member, KGH/HDH Joint Quality and Utilization Improvement Committee; Member, Pathology Continuing Education Committee; Chair, Pathology Quality & Utilization Improvement Committee.

**Dr. P. Greer:** Member, University Animal Care Committee; Member, Faculty Animal Advisory Group; Member, Faculty Microarray Service Management Committee; Member, Faculty Pathology Headship Search Committee; Member, Pathology PRTCA Committee; Member, Coordinator,

Pathology Graduate Committee; Pathology Staff Meetings; Internal Reviewer for Drs. Elliott, Cole and Craig CIHR grant applications.

**Dr. K. Harrison:** Member, KGH/Queen's Genetics Review Committee; Interviewer, Faculty of Health Sciences Medical School Interviews; Member, Phase I Genetics Teaching Planning Group; Member, Medical Admissions Committee; Member, Pathology LIS Prioritization Committee; Member, Pathology PRTCA Committee; Member, AP Search Committee; Member, Pathology Graduate Studies Committee; Member, Laboratory Genetics Administration Meetings; Coordinator Medical Genetics Grand Rounds; Member Research Lab Meetings; Chair, Clinical Genetics Work Rounds; Member, Pathology Clinical Trust Fund Committee; Member, Pathology Finance Committee; Member, Prenatal Procedures Meeting; Clinical Coordinator, Division of Laboratory Genetics; Member, KGH Cytogenetics Laboratory Journal Club.

**Dr. D. Hurlbut:** Member, AP and GP PGME Committee; External Member, Faculty GI Residency Training Program; Member, GI Site Group, KRCC.

**Dr. T. Karnauchow:** Member, AP/GP Residency Training Committee; Member, Pathology & and Clinical Laboratories Quality & Utilization Improvement Committee; Faculty Rep. Pathology and Laboratory Medicine Technologists' CME Committee; Member, Hospital Medical Microbiology Laboratory Administrative Committee; Member, KGH Antibiotic Use Subcommittee; Laboratory co-Representative, Infection Control Committee.

**Dr. M. Khalifa:** Chair, Prenatal Procedures Committee, KGH, Member, Division of Medical Genetics, KGH.

**Dr. R. Kisilevsky:** Member, Faculty Board, Queen's; Member, Pathology Staff Meeting; Member, Research Advisory Committee; Member, Pathology PRTCA Committee.

**Dr. D. LeBrun:** Member, Faculty Advisory Committee, Protein Function Discover Group; Member, Faculty Board; Member, Clinical Teachers Association; Member, Clinical Hematology Division; KGH Staff Meetings; Member, Graduate Studies Committee; Member, Residency Training Committee; Member, Pathology AP Search Committee; Member, Pathology Staff Meeting; Member, AP Group Meeting; Member, Medical Mortality Conference; Member, HP Division; Member, Internal Review of Pathology Programs.

**Dr. D. Lillicrap:** Member, University Animal Care Services Users Committee; Member, Faculty Research Advisory Committee; Chairperson, AA Travill Debate Committee; Member, Blood Utilization Committee, KGH; Chair, Pathology Research Advisory Committee; Member, Pathology PRTCA Committee; Chair, Medical Genetics Search Committee; Chair, Research Scientist Search Committee.

**Dr. S. Ludwin:** Associate Dean Research; Vice-President, Research Development, KGH.

**Dr. P.N. Manley:** Pathologist-in-Chief, HDH/KGH, (Jan 1-June30); Chairman, Dept. of Pathology, Queen's, (Jan 1-June30); Member, Faculty Council; Member, Faculty Board; Member, SEAMO Governing Committee; Member, SEAMO Finance Sub-Committee; Member, Basic Science Heads; Member, Council of Clinical Heads; Member, School of Medicine Council; Member, KGH Medical Advisory Committee; Member, KGH Medical Advisory Budget Review Committee; Member, Council of Department Heads; Member, CLEO Meetings, KGH; Chair, Departmental Search Committee; Chairman, HDH/KGH Joint Management Committee Meeting; Member, Lab Admin. Management Committee; Chairman, Pathology Finance Committee; Member, Lab Admin.

Management Committee; Member, Anatomic Pathology Meeting; Member, Pathology Search Committees; Member, Pathology Graduate Committee, Member, Pathology Postgraduate Committee.

**Dr. L. Mulligan:** Member, Cancer Research Institute Management Committee; Chair, CIHR Training Program; Member, CRC Tier I Search Committee; Member, Pediatrics Promotions Committee; Member, Pathology PRTCA Committee; Member, Pathology Clinical Geneticist Search Committee.

**Dr. D. Rapson:** Member, Hematopathology/Oncology Division; KGH Director of Hemostasis Core Laboratory; Co-Director KGH Autologous Blood Transfusion Program; Member, KGH Hemophilia Comprehensive Care Group; Member, Hematology/Oncology Residency Training Committee; KGH & Queen's Pathology Staff Meetings; Member, Pathology Quality Assurance and Improvement Committee, Member, Pathology Finance Committee; Member, South Eastern Regional Bone Marrow Transplant Planning Group; Member, Mentor Program for Medical Students, Member, PhD/MD working Group E2 Region..

**Dr. M. Raymond:** Chief, KGH Clinical Chemistry; KGH Staff Meetings; Queen's Pathology Staff Meetings.

**Dr. J.P. Rossiter:** Member, Neurology Residency Training Committee, Queen's; Member, Neuropathology Residency Training Committee, Queen's; Member, Faculty AP/GP Pathology Residency Training Committee; Faculty Life Sciences Curriculum Committee; Member, Faculty Postgraduate Medical Education Committee; Bracken Library Committee; Member, Botterell Foundation Grand Review Committee; Pathology Staff Meetings, KGH/Queen's; Pathology Clinical Trust Fund Review Committee; Member, Committee on Optimizing Autopsy Report TAT; Director, Neuropathology Residency Program; Coordinator, Pathology 410/824; Member, Internal Review Committee of Ophthalmology Residency Program.



**Dr. C. Rowlands:** Member, Faculty Admissions Committee; Member, Faculty Postgraduate Medical Education Committee; Member, Basic Clinic Year Subcommittee; Director, Cytology, KGH/HDH; Member, Pathology Residency Training Committee; Chair, Residency Program Committee; Staff Meetings, Queen's/KGH.

**Dr. S. SenGupta:** Member, Faculty UMEC Committee; Member, Faculty Phase II Musculoskeletal Course Committee; Chair, Block IIA Course Directors' Committee; Member, KGH/HDH Medical Advisory Committee; Member, Ongwanada Hospital Medical Advisory Committee; Member, KGH Joint Quality & Utilization Improvement Committee; Member, HDH Breast Assessment Program Patient Care Team; Member, Pathology Finance Committee; Member, AP Search Committee; Chair, Quality Assurance Committee; Member, Departmental PRTCA Committee; Queen's/KGH/HDH Staff Meetings; Member, East 2 Regional Laboratory Services Steering Committee.

**Dr. L. Shepherd:** Member, Senior Management Committee, Cancer Research Institute; Member, Faculty Postgraduate Education Committee; Interviewer, Medical School Admissions; Member, Joint Practice for Transplantation and Organ Procurement, KGH; Member, Joint Hospital Advisory Committee on HIV Notification of Blood Recipients; Chair, Advisory Committee on Transfusion Medicine; Member, Division of Hematology; Member, Training Committee, Fellowship Program in Clinical Hematology; Member, Planning Committee for Regional Stem Cell Transplant Program; Member, Hematological Path Training Program; Member, Consolidated Division of Hematology; Member, Pathology GP Training Committee; Member, Pathology Anatomical Pathology Training Committee; Chair, PRTCA Committee; Pathology Ad Hoc Search Committee, Hematopathology; Member, Tissue & Tumour Block Retrieval Committee; Member, NCIC CTG Search Committee..

**Dr. S. Taylor:** Acting Chair, University Biohazard Safety Committee; Member, Pathology PRTCA Committee; Co-Director, KGH DNA Laboratory; Chief of Service, Laboratory Genetics; Member, KGH Foundation Grants Committee; Member, Clare Nelson Bequest Fund Committee, KGH; Member, KGH Radiation Safety Committee; Queen's/KGH/HDH Staff Meetings.

**Dr. I. Young:** Director, Division of AP (to June 30); Member, Faculty Promotion Committee (to June 30); from July 1: Member, Council of Clinical Head; Member, Council of Basic Science Heads; Member, Faculty Council; Member, Faculty Board; Member, KGH Resources Committee; Member, KGH Administrative Director Search Committee; Member, KGH/HDH Joint MAC Committee; Chair, KGH/HDH Queen's Staff Meetings; Member, Pathology Graduate Studies Committee; Chair, Pathology Finance Committee; Member, Pathology Postgraduate Committee; Chair, AP Search Committee; Member, Nephrology Search Committee, Medicine; Member, Clinical Geneticist Search Committee; Member, Ontario Regional Laboratory Services Planning/Laboratory Regional Coordinating Committee, East 2 Region.

**Dr. D. Zoutman:** Chair, Faculty Phase IIA Infectious Diseases Course Committee; Member, Phase IIA Curriculum Committee; Chair, KGH/HDH Joint Infection Control Committee; Member, Joint KGH/HDH Antibiotic Utilization Committee; Member, KGH Standing Committee on Environmental Management; Member, SMOL Professional Advisory Committee; Member, Accreditation Steering Committee; Member, KGH/HDH Medical Advisory Committee; Member, KGH/HDH Medical Advisory Executive Committee; Member, KGH board of Directors; Chair, St. Vincent de Paul Hospital Infection Control Committee; Member, Microbiology Laboratory Management Committee; Chair, Infection Control Services Committee.

## EXTERNAL COMMITTEES

**Dr. S. Boag:** Head, Pathology & Lab Medicine Network, Cancer Care Ontario Southeastern Regional Council; Member, Laboratory Medicine Program Committee, Cancer Care Ontario; Lung Site Group, Kingston Regional Cancer Centre.

**Dr. S. Cole:** Member, Research Advisory Committee, Cancer Care Ontario; Member, Scientific Advisory Board, Ontario Senior Fellow/Clinician Scientist Award, CCO; Vice-Chair, Committee on Research, NCIC; Member, Oversight Committee on Centre for Behaviour Research and Program Evaluation, NCIC; Board of Directors, NCIC; Member, Canadian Scientific Advisory Committee, 10<sup>th</sup> World Lung Conference on Lung Cancer; Member, Nominating Committee, American Association for Cancer Research; Member, Pezcoller Foundation-AACR Selection Committee, AACR; Consultant, Eli Lilly Pharmaceutical Company; Member, Scientific Advisory Board, ActivePass Pharmaceuticals; Member, Scientific Advisory Board for ABC, Federation of European Biological Societies.

**Dr. C. Collier:** Chair, Professional Development Program, Canadian Society of Clinical Chemists and Canadian Academy of Clinical Biochemists; President-Elect, Ontario Society of Clinical Chemists; General Chemistry Committee, QMP-LS; Grading abstracts Online, AACC Annual Meeting & Clinical Laboratory Exposition.

**Dr. R. Deeley:** Vice-President, Division of Research, Cancer Care Ontario; Consultant, Merck Frosst Canada & Co.; Consultant, Eli Lilly; Member, Scientific Advisory Committee, OCRN; Member, Working Group, Canadian Strategy for Cancer Control; Member, Sounding board, Cancer Initiative Working Group, Member, Scientific Advisory Committee, Cytochroma Inc.; Member, Scientific Advisory Board, Ontario Centre for Protein Production; Chair, Celera Genome Database Grant Panel, CIHR.

**Dr. D. Dexter:** Director of Laboratories and Consultant in Hematology, MDS Laboratories; Consultant, Ontario Cancer Foundation, Kingston; Director, Forensic Unit, KGH; Director, Autopsy Service, KGH; Director, Point of Care Testing, HDH and KGH.

**Dr. B. Elliott:** Member, NCIC Grant Panel J; Chair, Pathobiology I Grant Panel, USAMRMC BCRP.

**Dr. K. Harrison:** Consultant, CHEO Cytogenetics Laboratory; Consultant, Oshawa Lakeridge Health Centre; Chair, Standing Fellowship Committee, CCMG; Proctor, CCMG Examination of Molecular Fellow; Examiner for Cytogenetics, CCMG; Proctor, Genetic Technology Student Exam, Michener Institute.

**Dr. D. Hurlbut:** Board Member, OAP; Chair, OAP Meeting.

**Dr. T. Karnauchow:** Member, Canadian Committee for the Standardization of Molecular Methods.

**Dr. M. Khalifa:** Exam Board Member, RCPSC; Member, MSS Consultation Group, OMH; Queen's Rep. Association of Professors of Human/Medical Genetics; Chair, PEACE Committee, Canadian College of Medical Genetics.

**Dr. R. Kisilevsky:** Member, Advisory Committee, IXth International Symposium on Amyloidosis; Member, Scientific Advisory Board, Institute for the Study of Aging; Editorial Advisory Board,

International Review of Experimental Pathology; Editorial Board, Amyloidosis: the International Journal of Experimental & Clinical Investigation.

**Dr. D. LeBrun:** Website Editor, CAP; Chair, Awards Committee, CSCI; Member, American Society of Hematology; Member, American Association for the Advancement of Science; Member, Ontario Medical Association.

**Dr. D. Lillicrap:** Member, Canadian Hematology Society; Member, American Hematology Society; Member, American Society for Gene Therapy; Member, Canadian Hemophilia Society; Chair, von Willebrand Disease State of the Art Conference, Canadian Hemophilia Society; Member, World Federation of Hemophilia; Member, Association of Hemophilia Clinic Directors of Canada (AHCDC); Chair, Steering Group, Management Information System, AHCDC; Chairperson, vonWillebrand Disease Scientific Subcommittee, Association of Hemophilia Clinic Directors of Canada; Member, Factor IX Scientific Subcommittee, Association of Hemophilia Clinic Directors of Canada; Member, Alberta Heritage Foundation for Medical Research; Review Panel Member, CIHR, Experimental Medicine, Grant Review Committee; Member, US National Hemophilia Foundation Medical and Scientific Advisory Council; Member, US National Hemophilia Foundation Gene therapy Working Group.

**Dr. S. Ludwin:** Chairman, MAC, Canadian Multiple Sclerosis Society; Myelin Project Board; President, International Society Neuropathology; Member of Executive and Member of Publication Committee, Medical Advisory Board, International Federation Multiple Sclerosis Societies.

**Dr. P. Manley:** Member, Association of Pathology Chairs (to June 30); Member, International G.I. Club; Member, Ontario GI Club; Member, CAP (US); Member, OMA; Member, OAP; Chair, Ontario Association of Academic Heads (to June 30); Secretary/Treasurer, Canadian Chairs of Pathology (to June 30); Member, North East Pathology Chairs (to June 30); Member, Laboratory Review Committee, OHA (to June 30); Member, East 2 Regional Steering Committee (to June 30); Member, Lab Steering Committee (to June 30).

**Dr. L. Mulligan:** Member, Biomedical Personnel Panel, NCIC; Member, Cancer “A” Panel, CIHR; Member, OCGS Appraisal Committee; Secretary, Genetics Society Cancer.

**Dr. D. Rapson:** Member, Examination Board for HP, RCPSC.

**Dr. M. Raymond:** Vice-Chair, Committee for Conjoint Accreditation, Canadian Medical Association; Chair, Medical Laboratory Program Advisory Committee, St. Lawrence College.

**Dr. J. Rossiter:** Member, Organizing Committee, CAP; Member, RCPSC Neuropathology Fellowship Examination Board.

**Dr. C. Rowlands:** Specialty Committee, Lab Medicine, AP and GP, RCPSC.

**Dr. S. SenGupta:** Past-President and Member of Executive Committee and Board of Directors, Member of LOC for AGM and Chair of Nominations Committee, Ontario Association of Pathologists; Member, Regional Advisory Committee, RCPSC; Member, National Specialty Societies Committee, RCPSC; President & Chair of Executive Committee, CAP; Member, Committee of Affiliates, CMA; Member, AP Committee, QMP-LS; Member, Test Review Committee, QMP-LS; Member, Ontario Laboratory Accreditation Advisory Panel, QMP-LS; Member, Ontario Breast Assessment Collaborative Group; Member, CCO Breast Cancer Disease Site Group.

**Dr. L. Shepherd:** Nucleus Member, Hematopathology Specialty Committee, RCPSC; Member, Laboratory Medicine Advisory Committee, RCPSC; Past Chair, Section of Hematopathology, CAP; Member, Laboratory Proficiency Testing Program, Immunology Committee; Central Director, Canadian Society of Transfusion Medicine Board.

**Dr. S. Taylor:** Chair & Secretary, Ontario Ministry of Health, Molecular Genetics Study/Working Group on Molecular Genetics Diagnostic Services; Chair, Fellowship Review Committee, MOH; Member, Ontario Cancer Genetics Management Committee; Member, Examination Committee, CCMG; Member, OMH Cancer Genetics Steering Committee; Chair, OMH Cancer Genetics Laboratory Subcommittee; Member, Organization and Evaluation of Laboratory Proficiency Tests, QMPLS Genetics Committee, Member Ontario Genetics Advisory Committee; Co-author/Expert, Canadian Coordinating Office for Health Technology Assessment..

**Dr. I. Young:** Member, USCAP; Member, OAP, Member, East 2 Regional steering Committee; (since July 1) – Member, Association of Pathology Chairs (US); Member, Ontario Association of Academic Heads; Member, Canadian Chairs of Pathology.

**Dr. D. Zoutman:** Member, Corrections Canada Infectious Diseases Inmate Advisory Committee; Chair, National Surgical Infection Surveillance Program, Canadian Hospital Epidemiology Committee; Member, Community & Hospital Infection Control Association of Canada, Standards & Guidelines Committee; Physician Director, Community and Hospital Infection Control Association of Canada; Member, Strategic Planning for Infection Control Guidelines, Health Canada; Member, Quality Management Program-Laboratory Services, QMPLS Bacteriology Committee; Chair, National Bioterrorism Contingency Planning Task Force, Health Canada; Director of Infections Prevention Program in the Balkans, Canadian International Development Agency and Canadian Public Health Association.

**EDITORIAL BOARDS  
AND  
GRANT REVIEW COMMITTEES**

## OTHER SCHOLARLY ACTIVITY

### EDITORIAL BOARDS AND GRANT REVIEW COMMITTEES

(Editorship of a journal, referee for journal or granting body, posters, productions, etc.)

**Dr. S. Boag:** Journal Reviewer for: Clinical Cancer Research, Tumour Biology, Cancer, Invasion and Metastasis.

**Dr. S. Cole:** Editorial Responsibilities: Editorial Board, Journal of Biological Chemistry; Associate Editor, Cancer Research; Deputy and Senior Editor, Molecular and Cancer Therapeutics; Co-editor ABC Transporters from Bacteria to Man; Editorial Academy International Journal of Oncology; International Advisory Board, Tumori.

Reviewer for: Dutch Cancer Society; CIHR; Association for International Cancer Research (UK); Cancer Research Campaign (UK).

Referee for: Biochemical Pharmacology, British Journal of Pharmacology, Cancer Research, Functional & Integrative Genomics, Gastroenterology, Gene, Journal of Bioenergetics and Biomembranes, Journal of Biological Chemistry, Journal of Clinical Investigation, Journal of Physiology, Molecular Cancer Therapeutics, Molecular Microbiology, Molecular Pharmacology.

**Dr. C. Collier:** Reviewer for Clinical Biochemistry.

**Dr. R. Deeley:** Referee for: American Journal of Physiology, Journal of Biological Chemistry, Biochemistry, Biochemical Pharmacology, Cancer Research, European Journal of Biochemistry, Molecular Pharmacology, Nature Medicine, Lung Cancer; Reviewer for: CIHR, NCIC, Netherlands Cancer Society; Editorial Board of Molecular Cancer Therapeutics.

**Dr. D. Dexter:** Editor and Contributor, Pathology Newsletter.

**Dr. B. Elliott:** External Grant Reviewer for CIHR.

External Reviewer: Cancer Research, Oncogene, Journal of Immunology and International Journal of Cancer.

**Dr. P. Greer:** Member, Panel H Review Committee, NCIC; Member, Grants Review Committee, Panel B, Ontario Cancer Research Network.

External Reviewer, Grants: Ontario Cancer Research Network, NCIC, Alberta Cancer board, Heart & Stroke Foundation.

External Reviewer for: Blood, Molecular and Cellular Biology, Oncogene, Comparative Biochemistry and Physiology, Journal of Cell Biology.

**Dr. K. Harrison:** Reviewer for: Immunohistochemistry, Molecular Medicine.

**Dr. M. Khalifa:** Referee for: Genetic in Medicine; American Journal of Medical Genetics, WHO Publications.

**Dr. D. LeBrun:** Grant Review Panels: KGH Pathology Clinical Trust Fund, Queen's Resident application for CSCI/RCPSC/PAIRO Canadian Research Awards for Specialty Residents

**Dr. D. Lillicrap:** Grant Panels: Heart & Stroke Foundation of Ontario, Alberta Heritage Foundation for Medical Research, CIHR, Canadian Stem Cell Network Scientific Review Committee, Bayer International Hemophilia Awards Review Committee.  
Journal Reviewer: Nature Genetics, Genomics, Proceedings of the National Academy of Science, Human Genetics, Blood, thrombosis and Hemostasis, American Journal of Human Genetics, Journal of Clinical pathology, British Journal of Hematology, Hemophilia, Transfusion, Clinical and Laboratory Hematology, Human Gene Therapy, Gene Therapy.

**Dr. S. Ludwin:** Editorial Advisory Board, Neuropathology and Applied Neurobiology; Editorial Board, Acta Neuropathological, Journal Neuropathology & Experimental Neurology and International Journal Surgical Pathology.

**Dr. P. Manley:** External Reviewer, Department of Pathology, Dalhousie University, Halifax, NS; External Reviewer, Department of Laboratory Medicine, IHN, Toronto.

**Dr. L. Mulligan:** Referee for the Following Journals: Medical Genetics, International Journal Cancer, Clinical Endocrinology and Metabolism, Genes Chromosomes and Cancer, Proceedings National Academy Science, USA, Oncogene, Human Genetics, Genomics, Archives Medicine, Thyroid, Human Gene Therapy; Ad Hoc Referee: CIHR, Hospital for Sick Children Foundation, National Cancer Institute of Canada, US Department Veterans Administration, Welcome Trust.

**Dr. M. Raymond:** Managing Editor, Clinical Biochemistry; Referee, Clinical Biochemistry; External Examiner: Northern Alberta Institute of Technology, Edmonton, Alberta and University of Alberta Hospital, Edmonton.

**Dr. J. Rossiter:** Internal Review of Neuropathology Residency Program, RCPSC.

**Dr. S. SenGupta:** President's Column, CAP Newsletter; Medical Director's Column, Kingston Hospitals' Laboratory Outreach Newsletter; Member, Laboratory Physicians and Scientists Human Resources Plan for E2 Region.

**Dr. L. Shepherd:** Co-Chair, Scientific Session – International Society for Blood Transfusion, Vancouver, BC.

**Dr. D. Zoutman:** Member, Editorial Board, Canadian Journal of Infection Control; Referee for: Canadian Journal of Infectious Diseases, Infection Control and Hospital Epidemiology, Physicians Services Inc. Foundation Grant Award, Canadian Medical Association Journal.

**FULL PAPERS PUBLISHED  
AND IN PRESS  
2002**



## FULL PAPERS PUBLISHED AND IN PRESS

Zhang, D-W., **Cole, S.P.C.** and **Deeley, R.G.** Determinants of the substrate specificity of multidrug resistance protein 1 (MRP1): role of amino acid residues with hydrogen bonding potential in predicted transmembrane helix 17. *J. Biol. Chem.* 277: 20934-20941 (2002).

Qian, Y-M., Grant, C.E., Westlake, C.J., Zhang, D., Lander, P.A., Shepard, R.L., Dantzig, A.H., **Cole, S.P.C.** and **Deeley, R.G.** Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [<sup>125</sup>I]LY475776 and azidophenacyl [<sup>35</sup>S]glutathione. *J. Biol. Chem.* 277: 35225-35231 (2002).

Lok, C-N., Lang, A.J., Mirski, S.E.L. and **Cole, S.P.C.** Characterization of human topoisomerase II $\beta$  (*TOP2B*) promoter activity: essential roles of the nuclear factor-Y (NF-Y) and specificity protein-1 (Sp1) binding sites. *Biochem. J.* 368: 741-751 (2002).

Waugh, J., **Collier, C.**, Day, A., Waugh, M. and **Raymond, M.** Proficiency Testing Performance: A Case Study with modeling. *Clin. Biochemistry*, 34:447-453, (2002)

Davies, R., **Collier, C.**, **Raymond, M.**, Heaton, J. and Clark, A. Indirect measurement of Bioavailable Testosterone with the Bayer Immuno 1 System. *Clin Chem* 48(2): 388-390, (2002)

Sivilotti, M.L.A., **Collier, C.P.** and Choi, S.B. The supramolar contribution of ethanol to serum osmolality. *Ann Emerg Med* 40:6 (letter), (2002)

Simpson, J.A., Labugger, R., Hesketh, G.G., D'Arsigny, C., O'Donnell, D., Matsumoto, N., **Collier, C.P.**, Iscoe, S. and Van Eyk, J.E. Differential Detection of Skeletal Troponin I Isoforms in Serum of a Patient with Rhabdomyolysis: Markers of Muscle Injury? *Clin. Chem.* 48(7) 1112-1114, (2002)

Conrad, S., Kauffmann, H-M., Ito, K-i., Leslie, E.M., **Deeley, R.G.**, Schrenk, D., and **Cole, S.P.C.** A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. *Pharmacogenetics* 12: 321-330, (2002)

Mao, Q., Qiu, W., Weigl, K., Lander, P.A., Tabas, L.B., Shepard, R.L. Dantzig, A.H., **Deeley, R.G.** and **Cole, S.P.C.** GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [<sup>125</sup>I]-LY475776: evidence of a major binding site in the COOH-proximal membrane spanning domain. *J. Biol. Chem.* 277: 28690-28699, (2002)

Haimeur, A., **Deeley, R.G.**, and **Cole, S.P.C.** Charged amino acids in the sixth transmembrane helix of Multidrug Resistance Protein 1 (MRP1/ABCC1) are Critical Determinants of Transport Activity. *J. Biol. Chem.* 277: 41326-41333, (2002)

Koike, K., Oleschuk, C.J., Haimeur, A., Olsen, S.L., **Deeley, R.G.**, and **Cole, S.P.C.** Multiple membrane associated tryptophan residues contribute to the transport activity and substrate specificity of the human multidrug resistance protein, MRP1. *J. Biol. Chem.* 277: 49495-49503, (2002)

**Elliott, B.**, Hung, W., **Boag, A.H.** and Tuck, A. The Role of Hepatocyte Growth Factor/Scatter Factor in epithelial-mesenchymal transition and breast cancer. *Can. J. Physiol. Pharmacol.* 80(2):91-102 (2002)

Qiao, H., Hung, W., Tremblay, E., Wojcik, J., Gui, J., Ho, J., Klassen, J., Schwall, R., Campling, B and **Elliott, B.E.** Constitutive Activation of Met Kinase in Non-Small-Cell Lung Carcinomas Correlates with Anchorage-Independent Cell Survival. *J. Cellular Biochem.* 86:665-677, (2002)

Lin, E., Hui, A., Tremblay, E., Schaefer, E. and **Elliott, B.E.** Ca<sup>2+</sup>-Dependent Cell-Substrate Attachment and F-Actin Assembly are Required for Endogenous c-Src Kinase Activity in Mammary Carcinoma Cells. *Exp. Cell. Res.* (2002) in press

- Postovit, L.M., Dutt, P., Dourdin, N., Park, M., **Greer, P.A.**, Graham, C.H. and Elce, J.S. Expression of MMP-2 and u-PA is dependent on Calpain in SV40 T-Antigen Transformed Fibroblasts. *Biochem. Biophys. Res. Comm.* 297:294-301 (2002)
- Craig, A.W.B. and **Greer, P.A.** Fer Kinase is Required for Sustained p38 Kinase Activation and Maximal Chemotaxis of Activated Mast Cells. *Mol. Cell. Biol.* 22(18) 6363-6374 (2002)
- Greer, P.A.** Closing in on the Biological Roles of Fps/Fes and Fer Protein-Tyrosine Kinases. *Nature Reviews Molecular Cell Biology* 3:278-289 (2002)
- McCafferty, D.M., Craig, A.W.B. and **Greer, P.A.** Absence of Fer Protein-Tyrosine Kinase Exacerbates Leukocyte Recruitment in Response to Endotoxin. *J. Immunol.* 168:4930-4935 (2002)
- Zirngibl, R., Senis, Y. and **Greer, P.A.** Enhanced Endotoxin-Sensitivity in Fps/Fes-nul Mice with Minimal Defects in Hematopoietic Homeostasis. *Mol. Cell. Biol.* 22:2472-2486 (2002)
- Carragher, N.O. Westhoff, M.A., Riley, D., Potter, D.A., Dutt, P., Elce, J.S., **Greer, P.A.** and Frame, M.C. V-Src Induced Modulation of the Calpain-Calpastatin Proteolytic System Regulates both Morphological Transformation and cell Cycle Progression. *Mol. Cell. Biol.* 22:257-269 (2002)
- Senis, Y.A., Sangrar, W., Zirngibl, R., Craig, A.W.B., Lee, D.H. and **Greer, P.A.** Fps/Fes and Fer Nonreceptor Protein-Tyrosine Kinases Regulate Collagen- and ADP-induced Platelet Aggregation. *J. Thrombosis and Hemostasis* (in press)
- Bayani, J., Zielenska, M., Pandita, A., Al-Romaih, K., Karaskova, J., **Harrison, K.J.**, Bridge, J., Sorenson, P., Thorner, P., Squire, J. ASKY identifies recurrent complex rearrangements involving chromosomes 8, 17 and 20 in osteosarcomas. *Genes Chromosomes and Cancer* (accepted June 17, 2002; published online September 15, 2002) Vol 36 (1): 7-16 (2003)
- Mai, K.T., **Isotalo, P.A.**, Guindi, M., Burns, B.F. and Parks, W. Intestinal epithelial lesions associated with signet ring cell carcinoma of the colon and small intestine. *Pathology.* 34:51-56 (2002)
- Isotalo, P.A.** and Donnelly, J.G.. Response to "Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A" [letter]. *American Journal of Medical Genetics.* 110:191-192 (2002)
- Isotalo, P.A.** and Lloyd, R.V. Presence of birefringent crystals is useful in distinguishing thyroid from parathyroid gland tissues [letter]. *American Journal of Surgical Pathology.* 26:813-814 (2002)
- Isotalo PA**, Ford, J.C. and Veinot, J.P. Miliary blastomycosis developing in an immunocompromised host with chronic lymphocytic leukemia [letter]. *Pathology.* 34:293-295 (2002)
- Isotalo, P.A.**, Robertson, S.J. and Futter, N.G. Urinary bladder urachal remnants underlying papillary urothelial carcinoma. *Archives of Pathology and Laboratory Medicine.* 126:1252-1253 (2002)
- Isotalo, P.A.** and Donnelly, J.G. Comment on "Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos" [letter]. *European Journal of Human Genetics.* 10:578-579 (2002)
- Hayden, R.T.**, Isotalo, P.A., Parrett, T., Wolk, D.M., Qian, X., Roberts, G.D. and Lloyd, R.V. **In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagnostic Molecular Pathology (in press)**
- Isotalo, P.A.**, Nascimento, A.G., Trastek, V.F., Wold, L.E. and Cheville, J.C. Extragenital adenomatoid tumor of a mediastinal lymph node. *Mayo Clinic Proceedings* (in press)
- Isotalo, P.A.**, Keeney, G.L., Sebo, T.J., Riehle, D.L. and Cheville, J.C. Adenomatoid tumor of the adrenal gland: a clinicopathologic study of five cases and review of the literature. *The American Journal of Surgical Pathology* (in press).

- Isotalo, P.A.**, Johnston, B. and Veinot, J.P. Cardiac pathology of thrombotic thrombocytopenic purpura causing sudden death [letter]. Pathology (in press)
- Bruckner, L., Korones, D., **Karnauchow, T.**, Hardy, D. and Gigliotti, F. High Incidence of Penicillin Resistance Among Alpha-Hemolytic Streptococci isolated from the Blood of Children with Cancer. J. Pediatr. 140:20-26 (2002)
- Khalifa, M.**, Cappon, S., Soboleski, D. and Armstrong, D. A New Mental Retardation Syndrome Associated with Ocular Colobomas, Cleft Palate, Genital, Skeletal And Craniofacial Abnormalities. AJMG, 107:237-242 (2002)
- Khalifa, M.** and Struthers, J.L. Klinefelter syndrome is a common cause for mental retardation of unknown etiology among prepubertal males. Clin Genet, 61 (1) 49-53 (2002)
- Khalifa, M.** and Cappon, S. Reply to the Letter to the Editor by Chodirker et al. "A not so 'new' mental retardation syndrome". AJMG , 111:107-108 (2002)
- Khalifa, M.**, Struthers, J.L., Carson, N. and McGill, M. Molecular Screening For Smith-Magenis Syndrome Among Patients With Mental Retardation Of Unknown Cause. JMG, 39: e59 1-6 (2002)
- Berkin, A., Szarek, W.A., and **Kisilevsky, R.** Synthesis and Biological Evaluation of a Radiolabeled Analog of Methyl 2-Acetamido-2,4-dideoxy- $\beta$ -D-xylo-hexopyranoside Directed Towards Influencing Cellular Glycosaminoglycan Biosynthesis. Carbohydrate Res.337: 37-44 (2002)
- Ohashi, K., **Kisilevsky, R.**, and Yanagishita, M. Affinity binding of glycosaminoglycans with  $\beta$ 2-microglobulin, Nephron 90: 158-168 (2002)
- Kisilevsky, R.** and Tam, S. P. Serum amyloid A, cholesterol metabolism, and cardiovascular disease. Pediatr. Pathol. Mol. Med.21: 291-305 (2002)
- Sipe, J. D., Merlini, M., Skinner, M., Westermarck, P., Benson, M., **Kisilevsky, R.**, and Bely, M. IX International Symposium on Amyloidosis, July 15-21, 2001, Budapest, Hungary. Amyloid 9: 52-65 (2002)
- Kisilevsky, R.**, and Szarek, W. A. S. Novel glycosaminoglycan precursors as anti-amyloid agents, part II. J. Mol. Neurosci. 19: 45-50 (2002)
- Inoue, S., Kuroiwa, M., and **Kisilevsky, R.** AA Protein in Experimental Murine AA Amyloid Fibrils: A High Resolution Ultrastructural and Immunohistochemical Study Comparing Aldehyde-fixed and Cryofixed Tissues Amyloid J. Prot. Folding Disorders 9: 115-125 (2002)
- Kisilevsky, R.**, Crandall, I., Szarek, W.A., Bhat, S., Tan, C., Boudreau, L., and Kain, K.K. Short-chain aliphatic polysulfonates inhibit the entry of *Plasmodium* into red blood cells. Antimicrob. Agents Chemother. 46: 2619-2626 (2002)
- Tam, S.P., Flexman, A., Hulme, J., and **Kisilevsky, R.** Promoting export of macrophage cholesterol: the physiological role of a major acute phase protein, serum amyloid A 2.1. J. Lipid Res. 43:1410-1420 (2002)
- Schurter, M., **LeBrun, D.P.** and **Harrison, K.J.** Improved technique for fluorescence in situ hybridization analysis of isolated nuclei from archival, B5- or formalin-fixed, paraffin-embedded tissue. Molecular Pathology 55 (2):121-124 (2002)
- LeBrun, D.P.** E2A basic Helix-Loop-Helix Transcription factors in Human Leukemia. Front. Biosci. (in press)

- Xie, Y, Zheng, H., Leggo, J., Scully, M-F., **Lillicrap, D.** A founder factor VIII mutation, valine 2016 to alanine, in a population with an extraordinarily high prevalence of mild hemophilia A. *Thrombosis and Hemostasis*, 87:178-179 (2002)
- Lillicrap, D.**, Poon, M-C., Walker, I., Xie, F., Schwartz, B.A. and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the Factor VIII/von Willebrand Factor concentrate, Haemate-P/Humate-P, administered in Ristocetin Cofactor Unit doses to patients with von Willebrand disease. *Thrombosis and Haemostasis*, **87:224-230** (2002)
- Poon, M-C., **Lillicrap, D.**, Hensman, C., Card, R., Skully, M-F., and members of the Association of Hemophilia Clinic Directors of Canada. Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study. *Thrombosis and Haemostasis*, 87:431-435 (2002)
- Hough, C., Kamisue, S, Cameron, C, Notley, C., Tinlin, S., Giles, A. and **Lillicrap, D.** Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. *Thrombosis and Haemostasis*, 87:659-665 (2002)
- Brown, B., **Lillicrap, D.** Dangerous liaisons: The role of “danger” signals in the immune response to gene therapy. *Blood*, 100:1133-1140 (2002)
- Notley, C., Killoran, A., Cameron, C., Wynd, K., Hough, C., **Lillicrap, D.** The canine Factor VIII 3'-Untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression *in vivo*. *Human Gene Therapy*, 13:1583-1593 (2002.)
- Verbruggen, B., Verbeek, K., van Heerde, W., Nováková, I., Hensman, C., **Lillicrap, D.**, Giles, A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda Factor VIII:C inhibitor assay. *Thrombosis and Hemostasis*, 88:362-4 (2002)
- Oakes, J., **Lillicrap, D.**, Hahn, PM, Reid, R.L. A survey of Canadian Gynaecologists' recommendations to oral contraceptive users about contraception in the perioperative period. *American Journal of Obstetrics and Gynecology*, 187:1539-43 (2002)
- Fung, K., Xie, Y.-G., Hall, S.F., **Lillicrap, D.P.** and **Taylor, S.A.** Genetic basis of Familial Meniere's Disease. *J. Otolaryngol*, 31:1-4 (2002)
- Chuah, M.K.L., Schiedner, G., Thorrez, L., Brown, B., Johnston, M., Gillijns, V., Hertel, S., Van Rooijen, N., **Lillicrap, D.**, Collen, D., VandenDriessche, T., Kochanek, S. Therapeutic Factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. *Blood*, Epublication 101:1734-1743 (2003)
- Lillicrap, D.** Gene expression: overview and clinical implications. *Vox Sanguinis* 83.Suppl 1: 77-9 (2002)
- Kinkley, S.M., Brown, B., Lyng, A.T., Harrison, W.K., Schep, G.N., Goddard-Hill, A.C., Aubrey, M.E., **Lillicrap, D.** and **Taylor, S.A.M.** Absence of Overt Iron Overload in Two Individual Compound Heterozygous for a 22 Base Pair Deletion of Exon 2 and the C282Y Missense Mutation of the Hfe Gene. *Clinical Genetics*, Letter to the Editor (In Press )
- Sharathkumar, A., **Lillicrap, D.**, Blanchette, V.S., Kern, M., Leggo, J., Stain, A.M., Brooker, L., Carcao, M.D. Intensive Exposure to Factor VIII is a Risk Factor for Inhibitor Development in Mild Hemophilia A. *Journal of Thrombosis and Haemostasis* (In Press)
- O'Brien, L., James, P., Othman, M, Cameron, C., Notley, C., Hagerdorn, C., Hough, C., O'Shaunessy, D., Rivard, G., Members of the Association of Hemophilia Clinic Directors of Canada, **Lillicrap, D.** A founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. *Blood* (In Press)
- Moscarello, M.A., Mak, B., Wood, D.D. and **Ludwin, S.K.** Paclitaxel Attenuates Clinical Disease in a Spontaneously Demyelinating Transgenic Mouse and induced Remyelination. *Multiple Sclerosis* 8:130-138 (2002)

**Ludwin, S.K.** Staging and Classifying Multiple Sclerosis Lesions: Pathogenetic, Clinical and Radiological Implications. *Neuroscience News* 4(4-5) (2002)

**Ludwin, S.K.** The Pathology of Demyelinating Diseases. In: *Encyclopedia of the Neurological Sciences*, published by Academic Press (in press)

Andrew, S.D., Capes-David, A., Delhanty, P., Marsh, D.J. **Mulligan, L.M.** and Robinson, B.G. A Mitogen Activated protein Kinase-Dependent Signaling Pathway in the Repression of RET. *Gene* 298:9-19 (2002)

Carter, M.T., Yome, J.L., Marcil, M.N., Martin, C.A., Vanhorne, J.B. and **Mulligan, L.M.** Conservation of RET Proto-Oncogene Splicing Variants and Implications for RET Isoform Function. *Cytogenetics and Cell Genetics* 95:169-176 (2002)

Andrew, S.D., Kuiper, M.J., Mansergh, F.C. Wride, M.A., Rnacourt, D.E. and **Mulligan, L.M.** Structural Variation in a Novel Zinc Finger Protein and Investigation of its Role in Hirschsprung Disease. *Gene Function and Disease* (in press)

Liu, V.C., Samy, E.T., Sham, M.H., **Mulligan, L.M.** and Tam, P.K.H. Glia Cell-Line Derived Neurotrophic Factor Family Receptors (GFRA) are Abnormally Expressed in Aganglionic Bowel of a Sub-Population of Patients with Hirschsprung's Disease. *Laboratory Investigation* (in press)

Saberi, F., Heyland, D.K., Howes, D., Lord, J., **Rapson, D.** and Jones, G. The Relationship Between Procalcitonin and Infection in Critically Ill Patients. Published in Proceedings of Toronto critical care Medicine Symposium, November 2002

Lord, J.A., Heyland, D.K., Howes, D., Jones, G. and **Rapson, D.** Activated Partial Thromboplastin Time Waveform Changes and Markers of Inflammation, Coagulation and Infection in the Critically Ill. Published in Proceedings of Toronto critical Care Medicine Symposium, November 2002

**Rossiter, J.P.**, Anderson, L.L., Yang, F. and Cole, G.M. Caspase-3 Activation and Caspase-Like Proteolytic Activity in Human Perinatal Hypoxic-Ischemic Brain Injury. *Acta Neuropathologica* 103:66-73 (2002)

Jackson, A.C., Melanson, M and **Rossiter, J.P.** Familial Herpes Simplex Encephalitis. *Annals of Neurology* 51(3):406-407 (2002) (Case Report in 'Letter' format)

Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Woods, W.G., Ogden, A., Weinstein, H., **Shepherd, L.**, Willman, C., Bloomfield, C.D., Rowe, J.M. and Wiernic, P.H. All-trans Retinoic acid in Acute Promyelocytic Leukemia: Long-term Outcome and Prognostic Factor Analysis from the North American Intergroup Protocol. *Blood*, 15;100(13):4298-4302 (2002)

Morrison, V.A., Rai, K.R., Peterson, B.L., Kolitz, J.E., Elias, L., Appelbaum, F.R., Hines, J.D., **Shepherd, L.**, Larson, RA and Schiffer, C.A. Therapy-related Myeloid Leukemias are Observed in Patients with Chronic Lymphocytic Leukemia after Treatment with Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B9011. *J. Clin. Oncol.* 15;20(18):3878-3884 (2002)

Martell, R.E., Peterson, B.L., Cohen, J.H., Petros WP, Rai KR, Morrison VA, Elias L, **Shepherd L**, Hines J, Larson RA, Schiffer, C.A. and Hurwitz, H. Analysis of Age, Estimated Creatinine Clearance and Pretreatment Hematologic Parameters as Predictors of Fludarabine Toxicity in Patients Treated for Chronic Lymphocytic Leukemia: a CALGB (9011) Coordinated Intergroup Study. *Cancer Chemother Pharmacol.* 50(1):37-45 (2002)

Pater, J.L., Parulekar, W., O'Callaghan, C., **Shepherd, L.**, Eisenhauer, E., Seymour, L., Tu, D. and Ding, K. Ethics and Industry-Sponsored Research. *CMAJ.* 5;166(5):581-2 (2002)

Ribic, C.M., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M., Hamilton, S.R., Laurent-Puig, P., **Shepherd, L.**, Tu, D., Redston, M. and Gallinger, S. Tumor Microsatellite Instability MSI and the Benefit of 5-FU Based Chemotherapy in Stage II and III Colon Cancer: a Pooled Molecular Reanalysis of Randomized Chemotherapy Trials. *NEJM* 2002 (in press)

Cataudella, J., **Young, I.D.** and Iliescu, E. Epstein-Barr Virus-Associated Acute Interstitial Nephritis: Infection or Immunologic Phenomenon? *Nephron* 92:437-439 (2003)

Peters, D.A., Watkins, J.F. and **Young, I.D.** Lymphoepithelioma-like Carcinoma of the skin. *Canadian Journal of Plastic Surgery* 10(5):220-222 (2002)

**Zoutman, D.**, Fleming, C. Quality Management Program-Laboratory services Microbiology Committee and Richardson H. Compliance with NCCLS Approved Standard M22-A2 for Bacteriologic Media Quality Assurance: A Survey of 124 Ontario Microbiology Laboratories. *Diagnostic Microbiology and Infectious Disease* 42:29-34 (2002)

Loeb, M., Brazil, K., Lohfeld, L., McGeer, A., Simcor, A., Stevenson, K., Walter, S., **Zoutman, D.** Optimizing Antibiotics in Residents of Nursing Homes: Protocol of a Randomized Trial. *BMC Health Services Research* 2:17-35 (2002)

Taylor, G.D., et al. and Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Prospective Surveillance for Primary Bloodstream Infections Occurring in Canadian Hemodialysis Units. *Infect. Control. Hosp. Epidemiol.* 23:716-720, (2002)

Stratford, A., **Zoutman, D.** and Davidson, J. The Effect of Lidocaine and Epinephrine in Staphylococcus Aureus in a Guinea Pig Model of Surgical Wound Infection. *Plastic and Reconstructr. Surg.* 110:1275-1279 (2002)

Miller, M.A. et al. and Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Morbidity, Mortality and Health-Care Burden of Nosocomia Clostridium Difficile-Associated Diarrhea in Canadian Hospitals. *Infect. Control. Hosp. Epidemiol.* 23:137-140 (2002)

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Central Venous Catheter-Associated Blood Stream Infections Occurring in Canadian Intensive Care Units: a Six Month Prospective Study. *Infection Control and Hospital Epidemiology* (in press)

**Zoutman, D.**, Ford, B.D. and Canadian Hospital Epidemiology Committee. The State of Infection Surveillance and Control in Canadian Acute Care Hospitals. *Am. J. Infect. Control.* (in press)

## BOOK CHAPTERS

**Cole, S.P.C.** and **Deeley, R.G.** Multidrug Resistance II - MRP and Related Proteins. In, Encyclopedia of Cancer - Second Edition (ed. J.R. Bertino). Volume 3, pp. 255-267, Elsevier Science, San Diego, CA. (2002)

**Cole, S.P.C.** and Tannock, I. Drug Resistance. In: The Basic Science of Oncology, 4<sup>th</sup> edition (eds. I. Tannock, R. Hill, R. Brostow and L. Harrington). Chapter 17, McGraw-Hill (in press 2003)

**Deeley, R.G.**, and **Cole, S.P.C.** Multidrug resistance protein 1 (ABCC1). In ABC Proteins: From Bacteria to Man. (eds. I.B. Holland, S.P.C. Cole, K. Kuchler and C.F. Higgins) pp. 393-422, Academic Press Elsevier Science, London (2002).

**Karnauchow, T.** general Microbiology Rapid Diagnostic Tests, In: The Kingston Hospitals Antimicrobial Handbook (Third Edition)

**Kisilevsky, R.** and Szarek, W.A. Novel Glycosaminoglycan Precursors as Anti-amyloid Agents, in Drug Discovery and Development for Alzheimer's Disease 2000, Eds. H. M. Fillit and A.W. O'Connell. Springer Publishing Company, New York, pp 98-105 (2002)

**Kisilevsky, R.** Biomedical Research Funding in Canada: An Exercise in Political Impact and Visibility. In: Statistics, Science and Public Policy VI. Science and Responsibility Proceedings of the Conference on Statistics, Science and Public Policy held at Herstonceux Castle Halisham, UK., April 18-21, 2001. Eds. A.M. Herzberg and R.W. Oldford. Queen's University, Kingston, ON. pp 91-98 (2002)

Gimm, O, **Mulligan, L.M.**, Suster, S., Komminoth, P., Morrison, C. and Sweet, K. Multiple Endocrine Neoplasia 2 in WHO Classification of Tumours of Endocrine Organs. IARC Press: Lyon (submitted)

**Mulligan, L.M.** "Chromosome 10" In: Encyclopedia of Molecular Medicine. Ed. Creighton, T.E. John Wiley and Sons. Inc. p. 1249.

**Shepherd, L.** Pamphlets published. 1) Blood Transfusion Information for Patients and Family; 2) Autologous Blood Donation Programme – Information for patients and Their Families; 3) The NCIC CTG Tumour Tissue Data Bank – Information for Pathologists; 4) The NCIC CTG Tumour Tissue Data Bank – Information for Patients; 5) Membership Brochure for the Canadian Society of Transfusion Medicine

**ABSTRACTS 2002**



## ABSTRACTS

**S.P.C. Cole** and **R.G. Deeley**. Human MRP1 and MRP2: broad spectrum ABC transporters of toxicological relevance. CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002. (*invited speaker*)

D-W. Zhang, **S.P.C. Cole** and **R.G. Deeley**. Determinants of the substrate specificity of multidrug resistance protein1 (MRP1): role of amino acid residues with hydrogen bonding potential in predicted transmembrane helix 17. CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002.

C.J. Westlake, Y. Qian, M. Gao, **S.P.C. Cole** and **R.G. Deeley**. Identification of the structural and functional boundaries of the multidrug resistance protein cytoplasmic loop3. CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002.

K-i. Nunoya, C. Grant, H. Imawaka, Y. Miyata, **S.P.C. Cole** and **R.G. Deeley**. Molecular cloning and pharmacological characterization of rat multidrug resistance protein (MRP) 1. CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002.

M. Muredda, K-i. Nunoya, R.A. Burtch-Wright, **S.P.C. Cole** and **R.G. Deeley**. Comparative analysis of the promoter regions of the human and rodent multidrug resistance protein 1 (ABCC1) genes. CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002.

M. Adachi, K-i. Nunoya, J. Sampath, D. Sun, G. Du, M. Leggas, C. Stewart, **S. Cole**, **R. Deeley** and J. Schuetz. The MRP4 gene transports cyclic nucleotides and is directly regulated by the PKA signalling pathway: implications for biological role. 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 6-10, 2002. Proc. Amer. Assoc. Cancer Res. 43: 2463 (2002).

C-N. Lok, A.J. Lang, S.E.L. Mirski and **S.P.C. Cole**. Characterization of the human topoisomerase II $\beta$  (*TOP2B*) gene promoter. 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

M. Muredda, K-i. Nunoya, **S.P.C. Cole** and **R.G. Deeley**. Comparative analysis of the human and rodent MRP1 promoters. 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

K-i. Nunoya, C. Grant, **S.P.C. Cole** and **R.G. Deeley**. Molecular cloning and pharmacological characterization of rat multidrug resistance protein (MRP1). 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

C. Westlake, Y. Qian, M. Gao, **S.P.C. Cole** and **R.G. Deeley**. Structural and functional boundaries of MRP1 cytoplasmic loop. 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

D-W. Zhang, **S.P.C. Cole** and **R.G. Deeley**. Determinants of the substrate specificity of multidrug resistance protein 1 (MRP1): role of amino acid residues with hydrogen bonding potential in predicted transmembrane helix 17. 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

**S.P.C. Cole** and **R.G. Deeley**. Transport of xenobiotic and endobiotic metabolites by the MRP-related transporters, IUPHAR XIVth World Congress of Pharmacology, San Francisco, CA, July 8, 2002. (*invited speaker*)

**S.P.C. Cole**. Structure-function studies of the human multidrug resistance protein (MRP) genes. 22nd International Symposium on "Xenobiotics and Host Responses", University of Occupational and Environmental Health, Kitakyushu, Japan, September 24, 2002.

J.A. Simpson, R. Labugger, G. Hesketh, C. D'Arsigny, D. O'Donnell, **C. Collier**, S. Iscoe, J.E. Van Eyk. Fast and slow skeletal TnI: potential serum markers of skeletal muscle injury and disease. AACC (2002).

J.S. Eisen, M.L.A. Sivilotti, **C.P. Collier**. Does urine screening for drugs of abuse change the management of ED patients? *Ann Emerg. Med.* (2002).

D. Benjamin, **C.P. Collier**, A.R. Morton, E.B. Toffelmire. Is troponin T an effective marker in a dialysis population? Canadian Society of Nephrology Annual Meeting, Ottawa, ON, March 2002.

R.L. Houlden, J.B. Raja, **C.P. Collier**, A.F. Clark, J.M. Waugh. Medical students' perceptions of an undergraduate research elective. Ontario Medical Education Network Symposium, Kingston, ON, May 31, 2002.

C.J. Oleschuk, K. Ito, **R.G. Deeley** and **S.P.C. Cole**. Substitution of Trp<sup>1242</sup> in transmembrane segment 17 alters the substrate specificity of human multidrug resistance protein, MRP3 (ABCC3). CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002. (*CJO - Honourable Mention for Best Graduate Student Poster Competition*).

E.M. Leslie, I. Letourneau, K.E. Weigl, **R.G. Deeley** and **S.P.C. Cole**. Functional and structural consequences of cysteine substitutions in the NH<sub>2</sub>-proximal region of human multidrug resistance protein 1 (MRP1). CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002.

A. Haimeur, **R.G. Deeley** and **S.P.C. Cole**. Role of charged amino acids on the substrate specificity and transport of the ABC transporter MRP1 (ABCC1). CSBMCB 45th Annual Meeting and 12th Winternational Symposium, Banff, Alberta, March 22-24, 2002. (*AH - Honourable Mention for Best Postdoctoral Fellow Poster Competition*).

I.J. Létourneau, **R.G. Deeley** and **S.P.C. Cole**. Investigation of nicotine conjugate metabolites as inhibitors of the human MRP-related proteins. 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

K.E. Weigl, E.M. Leslie, W. Qiu, D. Hipfner, **R.G. Deeley** and **S.P.C. Cole**. Topology studies of the multidrug resistance protein 1, MRP1. 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

C.J. Oleschuk, K-i. Ito, **R.G. Deeley** and **S.P.C. Cole**. Substitution of Trp<sup>1242</sup> in transmembrane segment 17 alters the substrate specificity of human multidrug resistance protein, MRP3 (ABCC3). 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

E.M. Leslie, R.J. Bowers, **R.G. Deeley** and **S.P.C. Cole**. Structural requirements for functional interaction of glutathione (GSH) tripeptide analogues with the human multidrug resistance protein 1 (MRP1). 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

K. Koike, C.J. Oleschuk, A. Haimeur, **R.G. Deeley** and **S.P.C. Cole**. Multiple tryptophan residues contribute to the transport activity of multidrug resistance protein 1 (MRP1/ABCC1). 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

D. Situ, A. Haimeur, **R.G. Deeley** and **S.P.C. Cole**. Characterization of charged amino acids in the third membrane spanning domain of MRP1: role in substrate specificity and transport. 5th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 29, 2002.

C.J. Oleschuk, **R.G. Deeley** and **S.P.C. Cole**. Substitution of Trp<sup>1242</sup> in predicted transmembrane segment 17 alters the substrate specificity of the human bile salt transporter, MRP3 (ABCC3), 53rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, November 1-5, 2002. (Abstract # 101257)

**B.E. Elliott**, Cooperative effect of c-Src tyrosine kinase and Stat3 in stimulating HGF expression and scattering in mammary carcinoma cells. Era of Hope DOD Breast Cancer Research Program Meeting. Orlando, FL, September 25-29, 2002.

T. Wright and **B.E. Elliott**. Hepatocyte growth factor interaction with its receptor, Met, in breast cancer. Era of Hope DOD Breast Cancer Research Program Meeting. Orlando, FL, September 25-29, 2002.

- L. Fan, C. Di Ciano, A.W. Craig, **P.A. Greer** and A. Kapus. The role of Fer kinase in the F-actin depolymerization-induced phosphorylation of cortactin. 42<sup>nd</sup> American Society for Cell Biology Annual Meeting, San Francisco, CA.
- N. Dourdin, P. Dutt, **P.A. Greer** and J.S. Elce. Calpain and apoptosis: absence of calpain activity confers resistance to apoptosis in mouse embryonic fibroblasts immortalized with T-Ag. 42<sup>nd</sup> American Society for Cell Biology Annual Meeting, San Francisco, CA.
- P. Dutt, N. Dourdin, D.E. Croall, J.S. Elce and **P.A. Greer**. Exploring calpain function by targeted disruption of calpain genes in mice. 42<sup>nd</sup> American Society for Cell Biology Annual Meeting, San Francisco, CA.
- L. Postovit, P. Dutt, N. Dourdin, M. Park, **P.A. Greer**, C.E. Graham and J.S. Elce. Calpain regulates MMP-2 and u-PA expression in SV40 large T antigen immortalized mouse embryonic fibroblasts. 42<sup>nd</sup> American Society for Cell Biology Annual Meeting, San Francisco, CA.
- K.A. Benigo, M. Dembo, J. Elce, P. Dutt, **P.A. Greer**, A. Huttenlocher and Y. Wang. Calpain is involved in regulating cell-substrate mechanical interactions during fibroblast migration. 42<sup>nd</sup> American Society for Cell Biology Annual Meeting, San Francisco, CA.
- A.W.B. Craig, Y.A. Senis and **P.A. Greer**. Fps/Fes and Fer protein-tyrosine kinases play redundant roles in regulating myelopoiesis. 31<sup>st</sup> Annual Meeting of the International Society of experimental Hematology, Montreal, Quebec.
- E. Van Melle, S. Taylor, J. MacKenzie, I. Sumargo, **K. Harrison**, E. Price, J. Raymond and M. Fleming. Using the team approach to enhance student learning through the use of computer technology in a first year medical genetics course. Society for Teaching and Learning in Higher Education (STHLE 2002), McMaster University, Hamilton, ON June 12-15, 2002 (abstract and presentation, Alan Blizzard award competition - honorable mention) (2002)
- J. MacKenzie and **K. Harrison**, Molecular cytogenetic identification of a chromosome 8 derived supernumerary marker chromosome: a clinical description. American Journal of Human Genetics 71s: 785. (poster presentation) (2002).
- K.J. Harrison** and C. Forster-Gibson. Clinical features associated with an add(18)(q21) representing partial duplication of chromosome 18. American Journal of Human Genetics 71s: 727. (poster presentation) (2002).
- K.J. Harrison**, M. Wing and **S. SenGupta**. Molecular cytogenetic evaluation of metastatic breast cancer demonstrating loss of HER-2/*neu* and chromosome 17 polysomy: a case report. Platform presentation at the Great Lakes Chromosome Conference, May 17-18, 2002.
- J. Bayani, M. Zielenska, A. Pandita, K. Al-Romaih, J. Karaskova, **K. Harrison**, J. Bridge, P. Sorenson, P. Thorner and J.A. Squire, J.A. SKY identifies recurrent complex rearrangements involving chromosomes 8, 17 and 20 in osteosarcomas. Platform presentation at the Great Lakes Chromosome Conference, May 17-18, 2002.
- C.J. Forster-Gibson L. Mercer and **K. Harrison**. Similar Physical and Behavioural Phenotypes in Two Men with dup(17)(p11.2p11.2). Society for the Study of Behavioural Phenotypes Annual Meeting Nov, 2002 (Platform presentation)
- P.A. Isotalo**, T.J. Sebo, R.V. Lloyd, D.L. Riehle and J.C. Cheville. Adenomatoid tumors of the adrenal gland: a clinicopathologic study of four cases. Canadian Association of Pathologists, Calgary, 2002.
- R.T. Hayden, **P.A. Isotalo**, T. Parrett, X. Qian, G.D. Roberts and R.V. Lloyd. In situ hybridization for the differentiation of *Aspergillus*, *Fusarium* and *Pseudallescheria* species in tissue section. United States and Canadian Academy of Pathology, Chicago, 2002. Abstract: *Modern Pathology*. 2002;15:273A.
- J.G. Donnelly, **P.A. Isotalo** and S. Detombe. Frequency and multigenic associations of polymorphisms in methionine synthase, cystathionine beta synthase and methionine synthase reductase genes in a neonatal population. American Association for Clinical Chemistry, Orlando, 2002. Abstract: *Clinical Chemistry*. 2002; 48 Suppl:A181-182.

J.G. Donnelly, **P.A. Isotalo** and S. Detombe. Multigenic Association of Mutations in the Methylene-tetrahydrofolate Reductase and Methionine Synthase Genes in Failed Pregnancy. American Association for Clinical Chemistry, Orlando, 2002. Abstract: *Clinical Chemistry*. 2002; 48 Suppl: A182.

**P.A. Isotalo, A.H. Boag, S.K. SenGupta** and K.V. Well-differentiated sclerosing liposarcoma of the spermatic cord: a case report and review of the literature. Ontario Association of Pathologists, Kingston, 2002.

**T. Karnachow**, D. Sikora and P. Sankar. Rapid detection of RSV: Abbott testpack performance at Kingston General Hospital, 2001-2002. Eighteenth Annual Clinical Virology Symposium of the Pan American Society for Clinical Virology, Clearwater Beach, Florida, May 2002 (poster).

**T. Karnachow**, D. Sikora and P. Sankar. Detection of RSV by Abbott testpack at Kingston General Hospital: Performance and impact on nasocomial transmission. Canadian Association for Clinical Microbiology and Infectious Diseases 70<sup>th</sup> Annual Conjoint Meeting on Infectious Disease, Halifax, NS, November 2002 (oral presentation).

W.A. Szarek and **R. Kisilevsky**. Glycosaminoglycans, Disease, and Strategies for Drug Development. 85<sup>th</sup> Canadian Society for Chemistry Conference. June 1-5, 2002. Vancouver, BC Canada.

**R. Kisilevsky** and S.P. Tam. Promoting Cholesterol Export from Macrophage Foam Cells - the Mechanism of Action of SAA2.1 and its Implications. Canadian Cardiovascular Congress. October 26-30, 2002. Edmonton, AB.

B.D. Hyndman, R. Bayly, G.A. Blobel and **D.P. LeBrun**. Recruitment of acetyl-transferase transcriptional co-activators by the n-terminal transcriptional activation domain of E2A oncogenic proteins results in acetylation of E2A itself. *Blood* 100 (11) 536a, 2002.

B. Brown, C.X. Shi, F. Grant, S. Tinlin, A. McKinven, S. Webster, F.L. Graham and **D. Lillicrap**. Preclinical trials of a helper-dependent adenoviral vector for the treatment of murine and canine models of hemophilia A. American Society of Gene Therapy 5<sup>th</sup> Annual Meeting, Abs 247, P54, June 2002.

L. Couto, Jiang, Haiyan, C. Scallan, X. Qian, S. Patarroyo-White, A. Parker, T. Liu, H. Chen, S. Powell, F. Wright, S. Tinlin, S. Webster, **D. Lillicrap**, R. Sarkar, H. Kazazian, V. Arruda, K. High, L. Meuse, K. Ohashi, M. Kay and A. McClelland. Hemophilia A gene therapy in mouse and dog models using an AAV-FVIII vector. American Society of Gene Therapy 5<sup>th</sup> Annual Meeting, Abs 254, P54, June 2002.

P. Ye, X. Ye, R. Sarkar, H. Kazazian, H. Jr., **D. Lillicrap**, R.J. Kaufman, A.R. Thompson and C.H. Miao. Therapeutic correction of hemophilia A mice was achieved by naked gene transfer of high expressing, liver-specific FVIII constructs. American Society of Gene Therapy 5<sup>th</sup> Annual Meeting, Abs 258, P55, June 2002.

T. VandenDriessche, G. Schiedner, L. Thorrez, L., Naldini, A. Follenzi, **D. Lillicrap**, D., Collen, S. Kochanek and M. Chuah. Gene therapy for hemophilia A using onco-retroviral, lentiviral and gutless adenoviral vectors. American Society of Gene Therapy 5<sup>th</sup> Annual Meeting, Abs 254, P54, June 2002.

F.E.M. Grant, B. Brown, C.X. Chi, F. Graham, S. Tinlin, A. McKinven and **D. Lillicrap**. Strain-specific differences in the generation of anti-factor VIII immune response in hemophilic mice treated with adenoviral gene therapy. American Society of Gene Therapy 5<sup>th</sup> Annual meeting, Abs 481, P65, June 2002.

M.L. Rand, M. Schmutz, D. Clark, **D. Lillicrap** and V.S. Blanchette. Stability of dilutions of the recombinant factor VIII Kogenate FS determined by one-stage and chromogenic assays using plasma-derived and concentrate standards. 44<sup>th</sup> Annual Meeting of the American Society of Hematology, Philadelphia 2002.

P. Ye, A.R. Thompson, R. Sarkar, H. Kazazian, Jr., **D.P. Lillicrap**, R.J. Kaufman, H.D. Ochs, D.J. Rawlings and C.H. Miao. Inhibitory antibody formation against factor VIII derived from different species after naked DNA transfer into hemophilia A mice. 44<sup>th</sup> Annual Meeting of the American Society of Hematology, Philadelphia 2002.

L. Couto, C. Scallan, H. Jiang, X. Qian, S. Patarroyo-White, A. Parker, T. Liu, H. Chen, S. Powell, F. Wright, S. Tinlin, S. Webster, **D. Lillicrap**, V. Arruda, K. High, M. Kay and A. McClelland. Hemophilia A gene therapy in

mouse and dog models using an AAV-FVIII vector. 44<sup>th</sup> Annual Meeting of the American Society of Hematology, Philadelphia 2002.

C. Hough, K. Tompkins, C. Cameron, J. Brady, A. Keightley, S. Raj, A. Day and **D. Lillicrap**. Variability of the platelet adhesive genotype: Influence on the incidence of unstable angina. 44<sup>th</sup> Annual Meeting of the American Society of Hematology, Philadelphia 2002.

P. James, C. Notley, C. Cameron, C. Hegadorn, L. O'Brien, C. Hough and **D. Lillicrap**. Clear familial cosegregation of the type 1 von Willebrand disease phenotype and VWF haplotypes in the Canadian type 1 VWD study. Submitted to The International Society on Thrombosis and Haemostasis XIX Congress 2003.

C. Notley, P. James, C. Cameron, C. Hegadorn, L. O'Brien, C. Hough and **D. Lillicrap**. The type 1/type2M von Willebrand disease dilemma: findings from the Canadian type 1 VWD study. Submitted to The International Society on Thrombosis and Haemostasis XIX Congress 2003.

L. O'Brien, P.D. James, M. Othman, C. Cameron, C. Notley, C. Hegadorn, J.J. Sutherland, C. Hough, G.E. Rivard, D. O'Shaunessey, the Association of Hemophilia Clinic Directors of Canada and **D. Lillicrap**. An ancient von Willebrand disease mutation that associates with a common haplotype in ~14% of type 1 von Willebrand disease patients. Submitted to The International Society on Thrombosis and Haemostasis XIX Congress 2003.

J. Sutherland, L. O'Brien, D. Weaver and **D. Lillicrap**. An *in Silico* analysis of type 2A von Willebrand disease mutations. Submitted to The International Society on Thrombosis and Haemostasis XIX Congress 2003.

J.A. Lord, D.K. Heyland, **D. Rapson** and D. Howes. Waveform abnormalities of a PTT in critically ill patients: a novel diagnostic marker in sepsis. Presented at Critical Care Meeting, Toronto, Ontario, October 2002.

L. O'Brien, J. Sutherland, K. Benford, H. Racz, **D. Rapson**, C. Hough and **D. Lillicrap**. A type 2A (Group II) von Willebrand disease mutation (Leu1503Glu) associated with a minimal loss of high molecular weight VWF multimers. Submitted to The International Society on Thrombosis and Haemostasis XIX Congress 2003.

**J.P. Rossiter** and M. Melanson. Combined tau and Lewy body pathology in a case of corticobasal degeneration. *Journal of Neuropathology & Experimental Neurology* 61(5):460, Abstract 72, 2002.

**J.P. Rossiter** and M. Melanson. Cerebral amyloid angiopathy (A $\beta$  peptide) with multifocal perivascular lymphocytic infiltrates and focal mural lymphocytic infiltrates: diagnostic case presentation. Canadian Association of Neuropathologists, 42<sup>nd</sup> Annual Meeting, 2002.

K. Pritchard, F. O'Malley, I. Andrulis, **L.E. Shepherd**, D. Tu, M.N. Levine and V.H.C. Bramwell. Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer (NCIC CTG MA.5). *Proceedings of ASCO*, Vol. 21, 2002

C.M. Ribic, D.J. Sargent, M.J. Moore, S.N. Thibodeau, A.J. French, R.M. Goldberg, S.R. Hamilton, P. Laurent-Puig, **L. Shepherd**, D. Tu, M. Redston and S. Gallinger. Tumor microsatellite instability MSI and the benefit of 5-FU based chemotherapy in stage II and III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials. *Proceedings of ASCO*, Vol. 21, 2002

M. Crump, T. Baetz, A. Belch, S. Couban, R. Meyer, K. Imrie, J. Yau, R. Myers, N. Paul, R. Turner, **L. Shepherd** and J. Iglesias. Gemcitabine, Dexamethasone, Cisplatin (GDP) Salvage Chemotherapy for Relapsed or Refractory Hodgkin's Disease (HD): A National Cancer Institute of Canada Clinical Trials Group Study. *Blood*, November 16, 2002, Vol. 100, No. 11.

M. Crump, T. Baetz, A. Belch, S. Couban, R. Meyer, K. Imrie, K. Howsan-Jan, R. Myers, G. Adams, R. Turner, N. Paul, **L. Shepherd**, and J. Iglesias. Gemcitabine, Dexamethasone, Cisplatin for Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL): A National Cancer Institute of Canada Clinical Trials Group Study. *Blood*, November 16, 2002, Vol. 100, No. 11.

B. Langer, H. Bleiberg, R. Labiance, **L. Shepherd**, D. Nitti, S. Marsoni, D. Tu, A.M. Sargeant and A. Fields. Fluorouracil (FU) plus 1-leucovorin (1-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proceedings of ASCO, Vol. 21, 2002

K.A. Stewart, C. Chen, K. Howson-Jan, D. White, J. Roy, M. Kovacs, C. Shustik, A. Sadura, **L. Shepherd**, K. Ding, R. Meyer and A. *Belch*. A randomized phase II dose-finding trial of thalidomide and prednisone as maintenance therapy for myeloma following autologous stem cell transplant. Proceedings of ASCO, Vol. 21, 2002

**Shepherd L**, Matthews J, Lee D, Smith AM. An Unusual Case of Post Transfusional Thrombocytopenia. Implications for the Blood Service Provider and Recipients. Abstracts of the 27<sup>th</sup> Congress of the ISBT, Vol. 83, Supp. 2, 2002, Vancouver, BC

Levine M, Pritchard K, Bramwell V, **Shepherd L**. A Randomized Trial Comparing CEF to CMF in Premenopausal Women with Node Positive Breast Cancer: Update of NCIC CTG MA.5. San Antonio Breast Cancer Conference, December 10-14, 2002.

Tonkin KS, Jackson S, Bramwell VHC, Hodsman A, **Shepherd L**, Pritchard KI. Lack of Effect of Tamoxifen (T) on Bone Loss in Pre and Peri-menopausal Women with Breast Cancer Rendered Postmenopausal after Adjuvant Chemotherapy ©: Results of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) Adjuvant Breast Study MA12, Bone Add-on Study. San Antonio Breast Cancer Conference, December 10-14, 2002.

**S. Taylor**, E. Van Melle, I. Sumargo, J. MacKenzie, M. Fleming, **K. Harrison**. Enhancing genetics education in medical school: an approach using a web-based course program. American Journal of Human Genetics 71s: 1019 (poster presentation) (2002).

G.D. Glendon, **S. Taylor**, W. Meschino, J. Allanson and I. Andrulis. Ontario Cancer Genetics Network from Research to Service: analysis at mutation Yield Comparing the Population based OFBCR and the OCGN BRCA1/2 Genetic Testing Eligibility criteria. American Society of Human Genetics Annual Meeting, Abstract #360, 2002.

E. VanMalle, **S. Taylor** and J. MacKenzie. Using a team approach to enhance student learning through the use of technology in a first year medical genetics course. Society for Teaching and Learning in High Education Annual Meeting, Abstract #149, 2002.

J. Cataudella, **I.D. Young** and E. Iliescu. Epstein-Barr virus – associated acute interstitial nephritis: infection or immunologic phenomenon? Canadian Society of Nephrology Annual Meeting, 2002.

B. du Prey, D. Ford, A. Bassili and **D. Zoutman**. Antimicrobial treatment recommendations by primary healthcare providers for common infections in Kenya. Community and Hospital Infection Control Association (CHICA) Canada, St. John's, June 2002.

**D. Zoutman** and J. Gauthier. Reduction in ventilator associated pneumonia rates: a multidisciplinary approach. Community and Hospital Infection Control Association (CHICA) Canada, St. John's, June 2002.

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Surveillance for cerebrospinal fluid (CSF) shunt associated infections – a Canadian nosocomial infection surveillance program (CNISP). Presented at the Annual Scientific Meeting of the Society for Health care Epidemiology, Salt Lake City, UT, April 2002.

Microbiology Committee of the Quality Management Program Laboratory Services of Ontario (includes **D. Zoutman**). External quality assessment of antimicrobial susceptibility testing of Streptococcus pneumoniae ATCC® 49619. Abstract presented at the Annual Scientific Meeting of the American Society for Microbiology, Salt Lake City, UT, May 2002.

J. fund, **D. Zoutman**, D. Campbell, D. Ford and K. Nakatsu. Impacts of a computer order-entry system on antibiotic use in a complex continuing care and rehabilitation facility. Community and Hospital Infection Control Association (CHICA) Canada, St. John's, June 2002.

H. Richardson, C. Fleming, F. Jamieson, C. Rutherford, M. Sarina, B. Toye, **D. Zoutman** and D. Low. Quality Management Program Laboratory Services of Ontario. Laboratory acquired shigella flexneri infections. Abstract presented at the Annual Scientific Meeting of the Canadian Association for Clinical Microbiology and Infectious Diseases, Halifax, NS, November 2002.

H. Richardson, C. Fleming, **D. Zoutman** and the Microbiology Committee. Quality Management Program Laboratory Services of Ontario. Blood culture practices in Ontario. Abstract presented at the Annual Scientific Meeting of the Canadian Association for Clinical Microbiology and Infectious Diseases, Halifax, NS, November 2002.

A. Bassili, D. Ford, B. du Prey and **D. Zoutman**. The antimicrobial treatment of common infections by pharmacists/pharmacy assistants in Kenya. American Society for Healthcare Pharmacists, Mid-year Clinical Meeting, Atlanta, December 2002.

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Methicillin-resistant Staphylococcus aureus (MRSA) surveillance in Canada, 1995-2001. Presented at the Annual Scientific Meeting of the International Symposium on Staphylococci and Staphylococcal Infections. Tokyo, Japan, October 2002.